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Plants have always been fundamental to traditional medicine. Chemists and the 
pharmaceutical industry screen plants to find new medicinal natural products for 
commercial drugs. Typically, this has been done either through random screening of 
plants or by focussing on plants used by traditional medicinal systems. Both of these 
screening methods are inefficient, owing to the diversity of plants and the wealth of 
natural products plants produce. New methods of screening plants for medicinal 
potential could fast-track this process, with significant benefits for human health. 
Medicinal plant natural products are typically specialised metabolites, which are 
produced in response to abiotic and biotic stressors. One of the major drivers in the 
evolution of plant specialised metabolism is herbivore stress, in which grazing by 
animals (often insects) triggers the production of metabolites that deter herbivores, and 
therefore act as defence compounds. Specialised metabolites are often genetically 
determined and affect plant survival, and hence they are under natural selection.  Due 
to this evolutionary process, related plant species tend to express similar specialised 
metabolites. Therefore, the medicinal potential of plants could be explored more 
systematically by using knowledge of their evolutionary relationships.  
This systematic, evolutionary approach can be further accelerated by using new high-
throughput metabolomic screening to describe which metabolites are present in the 
plants. This method typically, though, requires that these compounds have previously 
been identified and structurally elucidated, which is often not the case. However, this 
issue can be addressed by using novel molecular networking techniques, which can 
identify potential medicinal analogue metabolites that may have similar chemical (and 
hence bioactive) properties. Combining evolutionary and metabolomic approaches 
therefore provides an efficient method of identifying medicinal plants as well as 
potential medicinal plant metabolites. In my research I combined these approaches to 
identify potential medicinal plants and metabolites from the Australasian magnoliids, a 
clade that has been previously identified as one with a high incidence of medicinal use 
in both traditional medicine and formal scientific analyses.  
First, I conducted a broad survey of medicinal use and metabolites in the Australasian 




taxa (n = 108 species) and carried out metabolomic screening, followed by comparative 
metabolomic analysis and molecular networking. The overall metabolomic similarity 
analysis revealed that related magnoliids were chemically more similar. Molecular 
networking analysis identified seven putative metabolites of medicinal importance. The 
results demonstrate the utility of metabolomic analysis and molecular networking, in 
identifying novel potential medicinal metabolites from previously un-investigated 
plants. Next, I conducted a phylogenetic analysis of the magnoliid taxa as the basis for 
quantifying phylogenetic signal in traditional medicinal use and metabolites of 
medicinal potential. As with previous studies, the plant species used in traditional 
medicine showed significant phylogenetic clustering. There was significant 
phylogenetic signal for 11 metabolites. Likewise, molecular network clusters associated 
with two metabolites showed significant phylogenetic signal. These results highlighted 
that the medicinal potential of certain plant lineages is phylogenetically conserved and, 
when combined with metabolomic analysis and molecular networking, could allow 
identification of potential medicinal taxa worthy of further investigation. 
It is not always possible to carry out metabolomic analysis for all the taxa from a plant 
clade. In such instances, it may be possible to predict the medicinal potential of a taxa. 
Phylogenetic eigenvector mapping is one approach that can be used to predict the 
metabolomic profile of a target taxon for which metabolomic profiling is not possible.  
I used this approach to predict the medicinal potential of ten species from the magnoliid 
phylogeny, and found that, with phylogenetically conserved metabolites, predictive 
capacity is reasonably accurate (>60% correct). Further, the degree of accuracy of 
prediction was robust to the degree of phylogenetic signal. 
My results indicate that medicinal potential is not randomly distributed across the 
phylogeny of magnoliids. There is significant phylogenetic conservatism in the 
expression of medicinal metabolites across the clade. Molecular networking proved to 
be an efficient approach to identify both potential medicinal compounds and taxa 
expressing those metabolites. Further, phylogenetic eigenvector mapping is a promising 
approach to predicting the medicinal potential of plant taxa. This approach could be 
broadly applied across the plant kingdom to identify taxa with key desirable traits for 
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Natural products have always been used as medicine by humans and their pre-human 
ancestors. These natural products, which are typically secondary metabolites or 
specialised molecules are the end products of gene expression in living organisms 
(David et al., 2015). These metabolites are present in almost all organisms:  plants, 
animals, fungi and microorganisms. Most are biologically active (having the ability to 
act on cellular targets), a property which makes some ideal candidates for lead 
compounds for new drug development (David et al., 2015).  Indeed, the majority of 
therapeutics on the market today can be traced back to a natural product or a natural 
product derivative, highlighting the vast contribution of natural products to the 
pharmaceutical industry and human/animal health (Newman and Cragg, 2016).  
Plant-based natural products have formed the basis for many well-documented 
traditional medicinal systems (Cragg and Newman, 2013a). The use of plants as a 
source of medicines has a long history. Use of plants as a source of medicine was 
documented by the Mesopotamian and the Egyptian civilizations and evidence for the 
use of salicylic acid by Neanderthals has also been found (Dias et al., 2012, Pan et al., 
2014, Shipley and Kindscher, 2016, Weyrich et al., 2017). Plants are a vital component 
of ancient Chinese and Ayurvedic medicine in the Indian subcontinent (Newman and 
Cragg, 2012, Atanasov et al., 2015) and also in Central American, South American and 
the African traditional medicine (Fabricant and Farnsworth, 2001). Even today, 11% of 
the essential drugs identified by the World Health Organization (WHO) are taken 
directly from plants (Rates, 2001, Molina-Venegas et al., 2018). 
Of the more than 300,000 plant species in the world, around 28,000 plant species are 
recorded as having therapeutic properties, with only 16% of those having been tested 
for biological activity (Willis, 2017). In the past, scientific screening of plants for 
medicinal  compounds was either random or based on traditional knowledge of 
medicinal plants and field observations (Emerson Ferreira et al., 2009). Initial 
identification of plants with medicinal potential was followed by the isolation of 
specific medicinal compounds to provide single molecule drugs that could be used for 
their therapeutic properties (Miller, 2011). Over 40% of the United States Food and 
Drug Administration (USFDA) approved natural molecular entities between 1930-2013 
were plant-derived, yet towards the latter years there was a decline in plant natural 




medicinal natural products, and overall process of identifying the target taxa for 
investigation, the entire process was time consuming (Atanasov et al., 2015). Adding 
to these issues was the difficulty of extracting botanic natural products in sufficient 
quantities, leading to a rapid decline of the use of plants as sources of novel drug 
candidates (Raskin et al., 2002, Atanasov et al., 2015, David et al., 2015). The 
development of high throughput synthetic chemical techniques in the late 1980s also 
changed the focus of drug discovery from natural sources to drugs by design (Cragg 
and Newman, 2013b). Yet there are limitations of synthetic drug use, owing to some of 
their potential side effects and the expense related to the complexity of their chemical 
synthesis (David et al., 2015). Tellingly, more than 70% of the world population still 
rely on traditional natural product-based medicine and are unable to afford synthetic 
drugs (David et al., 2015).  
Despite this past downturn, plant-derived drugs are now entering the market in 
increasing numbers (Figure 1.1). During late 2000s there was a renewed interest into 
exploring natural products for pharmaceuticals, due to the low productivity in 
combinatory chemistry drug design (David et al., 2015). For example, well over 60% 
of anti-cancer drugs are of plant origin (Fridlender et al., 2015). In the United States 
alone there is a 5-15% annual growth rate of herbal pharmaceuticals, and there has been 
a re-emergence of botanic therapeutics in the past ten years (David et al., 2015). There 
is still a wealth of medicinal plants and plant natural products that could still prove to 
be a viable source of drug candidates, if the process could be streamlined. Hence, we 
require efficient, novel screening methods to identify medicinal plants and, isolate and 






Figure 1.1: Some of the most notable events in plant-based drug discovery from the past two hundred years 
(Based on the information in; (Beutler, 2009, Yun et al., 2012, Patridge et al., 2016), (Abbreviations: United States Food and Drug 




Targeting source plants is the first step in the drug discovery process. Conventionally, this 
requires researching the wealth of knowledge in traditional cultures, followed by taxonomic 
identification (Emerson Ferreira et al., 2009). However, this approach limits the search to the 
known/documented therapeutic plants, may risk over-harvesting or commercial control of 
culturally-important plants, and also involves ethical considerations about the sharing and 
ownership of long-held and developed cultural knowledge (Chen et al., 2016). Therefore if we 
could systematically identify the specific plant groups that have a higher propensity to be 
medicinal, the process of drug discovery would open up a much larger range of plant species 
for screening, and may reduce the risk of exploiting both wild plant populations, and cultural 
intellectual knowledge. This approach could then be coupled with novel advancements in 
metabolomics to screen for potentially medicinal compounds. In this thesis I examine the 
capacity of metabolomic screening combined with phylogenetic knowledge to predict 
medicinal use in a clade of early angiosperms, the magnoliids, in Australasia.  
 
1.1 Why use magnoliids to predict medicinal use?  
Magnoliids evolved close to 125 million years ago, and today comprise over 10,000 species 
belonging to four orders; Canellales (including Australian mountain pepper), Laurales 
(including cinnamon), Magnoliales (including the magnolias) and Piperales (including black 
pepper) (Massoni et al., 2015). The magnoliids have a rich evolutionary history being one of 
the first major radiations of angiosperms (Soltis and Soltis, 2004, Massoni et al., 2015, Soltis 
and Soltis, 2019). The clade is characterised by emission of diverse volatile compounds and 
specialised metabolites, from the flowers, leaves, bark and wood (Chaw et al., 2019). These 
spicy compounds likely evolved to deter herbivores, but may also play a role in attracting 
pollinators. The distinct chemistry of the magnoliid lineage has resulted in many being used as 
essential oils, traditional medicine or spices (Chaw et al., 2019). Well-known magnoliids used 
as spices include: bay leaves (Laurus nobilis L.), cinnamon (Cinnamomum verum J.Presl), 
nutmeg (Myristica fragrans Houtt.) and pepper (Piper nigrum L.). Other cultivated magnoliids 
include avocado (Persea americana Mill.) and custard apple (Annona reticulate L.). The best 
known species used for traditional purposes is perhaps kawakawa (Piper excelsum G.Forst.).  
In Australia and Aotearoa/New Zealand, magnoliids are widely used in traditional medicines 




Zealand is rich in magnoliid diversity, with close to 350 species (Wilson, 2007). Yet relatively 
few taxa have been investigated for their full medicinal potential and their phytochemical 
importance. A rare example of scientific testing of Magnoliid indicates they are one of 
angiosperm clades with highest bioactivity against three human cancer cell lines (Coley et al., 





Table 1.1: Medicinal use of widely known magnoliids in Australia and Aotearoa/ New Zealand 





Laurales Atherospermataceae Atherosperma 
moschatum Labill. 
Black sassafras gastrointestinal 
disease  
(Lassak and Mccarthy, 
2011) 





(Brophy et al., 2016) 













Grey sassafras  antimalarial  (Buchanan et al., 2009) 




antimalarial (Buchanan et al., 2009) 
  Laurelia novae 
zelandiae  
A.Cunn. 
Pukatea  gastrointestinal 
disease, pain 
relief and skin 
diseases  
(Brooker et al., 1987, 














pain relief  (Setzer et al., 2001) 
  Hedycarya 
arborea  J.R.Forst. 
& G.Forst. 
Pigeonwood medicinal vapour 
baths 
(Brooker et al., 1987, 
Brophy et al., 2016) 
Laurales Lauraceae Cassytha filiformis 
L. 
Love vine pain relief and 
aphrodisiac   
(Atlas of Living 
Australia, 2019) 




thermoregulation   (Lassak and Mccarthy, 
2011) 




(Brophy et al., 2001) 
  Cinnamomum 
oliveri F.M.Bailey 
Cinnamonwood skin diseases and 
inflammation  
(Lassak and Mccarthy, 
2011) 
  Litsea calicaris 
(A.Cunn.) Benth. 











disease and pain 
relief 










  Pseudowintera 
colorata (Raoul) 
Dandy  
Horopito pain relief  (Ngā Tipu Whakaoranga 
Database) 








(Winnett et al., 2014) 
  Tasmannia 
stipitata (Vickery) 
A.C.Sm. 
Dorrigo pepper gastrointestinal 
disease  
(Hart et al., 2014) 
Magnoliales  Eupomataceae Eupomatia laurina  
R.Br. 
Bolwarra  gastrointestinal 
disease  
(Khan et al., 2003, 
Bryant and Cock, 2017) 







(Gutierrez et al., 2016) 
  Piper auritum  
Kunth. 
Hoja santa  gastrointestinal 
disease and pain 
relief  
(Martínez et al., 1996) 
  Piper caninum 
Blume 
Common piper antiseptic (Salehi et al., 2019) 
  Piper excelsum  
G.Forst. 
Kawakawa neurological 











  Piper methysticum  
G. Forst 
Kava  Antidepressant  (Whitton et al., 2003) 
  Piper novae 
hollandiae Miq.  





1.2 Metabolomics to identify potentially medicinal plants  
Metabolomics could be used to screen plants for their medicinal compounds. Metabolomics is 
the qualitative and/or quantitative characterization of the small molecule profile of an organism 
or a tissue (Shyur and Yang, 2008). Metabolomic analysis can either be targeted or non-
targeted. In a non-targeted analysis, the aim is to characterise as many distinct metabolites as 
possible in a single analysis of a sample (Ribbenstedt et al., 2018).  This is a comprehensive 
screening process used for a range of applications including the identification of medicinal 
metabolites in a plant sample, since a single plant sample could harbour a huge range of 
secondary/specialised metabolites. The screening can be achieved using chromatography 
techniques coupled with mass spectrometry (MS) (i.e. gas chromatography mass spectrometry 
(GC-MS) and liquid chromatography mass spectrometry (LC-MS)) or nuclear magnetic 
resonance (NMR) spectroscopy. MS techniques are more sensitive than NMR which makes 
them an ideal metabolomic technique for non-targeted analysis (Wolfender et al., 2006, Sturm, 
2007). When considering both LC-MS and GC-MS, LC-MS is more informative for crude 
plant extracts and allows more comprehensive detection of thermally stable plant secondary 
metabolites (Wolfender et al., 2006).  
The plant kingdom is estimated to harbour more than 200,000 metabolites, yet only a fraction 
of these have been characterised, meaning that the data in spectral libraries are also limited 
(Fiehn, 2002, Hartmann, 2007, Pichersky and Lewinsohn, 2011). The techniques of 
metabolomics have advanced rapidly during the last decade. Foremost among these novel 
techniques is molecular networking, which emerged in the late 2000s and enables putative 
identification of metabolites based on spectral similarity comparisons of mass spectra (Yang et 
al., 2013, Wang et al., 2016). Molecular networking uses tandem mass spectrometry (where a 
parent ion (MS) generated in the mass spectrometer is further dissociated to fragment ions 
(MS/MS) to explore the structural similarities of metabolites across known metabolite libraries 
(Yang et al., 2013, Duncan et al., 2015). These networks organise MS/MS spectra into groups 
depending on the fragmentation patterns, with structurally-related metabolites possessing 
similar fragmentation patterns (and potentially similar chemical properties). This technique 
allows the identification of structurally related compounds and, in some cases, potentially 
previously-undescribed medicinal compounds. Molecular networking has become increasingly 




and microorganisms have been identified with this approach (Yang et al., 2013, Allard et al., 
2016, Naman et al., 2017, Quinn et al., 2017, Oppong-Danquah et al., 2018).  
 
1.3 Using evolutionary knowledge and chemosystematics to identify medicinal plant 
clades  
Identification of medicinally useful plants could be streamlined by considering the mechanisms 
underlying the evolution of metabolites. In the early 1990s research on plant chemosystematics 
(the classification of plants based on biochemical similarities: (Reynolds, 2007) found that the 
expression of particular medicinal secondary metabolites appeared to be lineage-specific, with 
closely-related taxa tending to produce similar metabolites (Wink, 2003, Rønsted et al., 2008, 
Yessoufou et al., 2015, Courtois et al., 2016). This characteristic has been attributed to the 
evolutionary significance and adaptive importance of specialised metabolites. Specialised 
metabolites can be induced by plants in response to biotic and abiotic stressors. Biotic stressors 
include pathogen/ herbivore attack, allelopathic chemicals of adjacent plants and effects of the 
soil microbiome. Recent evidence also points out that some of the pathogen/herbivore-induced 
specialised metabolites also increase the plants’ allelopathic effect on adjacent plants (Inderjit 
et al., 2011). From a co-evolutionary perspective the biotic stresses imposed by herbivores and 
pathogens drive the production of specialised metabolites, that are the product of coevolution 
with specific herbivores (Moore et al., 2019). Therefore, the genes related to specialised 
metabolism are conserved across lineages, which results in related species producing similar 
specialised metabolites.  
This evolutionary conservatism in medicinal properties and metabolite expression has directed 
natural product chemists and evolutionary biologists to examine phylogenetic patterns in 
bioactivity.  For example, studies of biological activity of angiosperms have led to the 
identification of a number of plant clades with significantly higher bioactivity based on their 
secondary metabolite profiles (Coley et al., 2003, Zhu et al., 2011). As examples the alkaloids 
with acetylcholine esterase inhibitory activity in daffodils Narcissus L., have been found to be 
phylogenetically constrained (Rønsted et al., 2008).  Similar patterns have been observed in 
the antimalarial alkaloids of Cinchona L., leaf succulence of Aloe L. (a trait linked to medicinal 
use of this plant), alkaloids of Amaryllidaceae and the antimalarial compound artemisinin in 




Maldonado et al., 2017, Pellicer et al., 2018).  Significantly, this tendency for related species 
to produce similar compounds, and for certain clades to have higher likelihoods of medicinal 
potential, can be used by natural product chemists to look for drug-producing plant families 
(Saslis-Lagoudakis et al., 2015). Therefore instead of the random screening of plants for 
biological activity, non-random screening processes based on phylogenetic knowledge could 
be adopted to identify potential target taxa for lead compound screening. 
 
1.4 Combining metabolomic and phylogenetic information to identify medicinal 
plants  
Evolutionary and chemosystematic studies provide information on potentially medicinal plant 
clades (Saslis-Lagoudakis et al., 2012, Negrin et al., 2019), with high abundance of medicinal 
specialised metabolites. Once identified, it is possible to screen these plants using non-targeted 
mass spectrometric analysis. The resultant mass spectra can be analysed with molecular 
networking to identify analogue compounds and the species expressing these potentially 
medicinal metabolites. Hence this will highlight certain plant clades/taxa which are worthy of 
further investigation. Overall this method would allow the prediction of the medicinal potential 
of non-target species.  
Identification of any metabolite phylogenetic patterns can be achieved through phylogenetic 
signal analysis. A phylogenetic signal is the tendency of two closely related taxa to be similar 
(Blomberg et al., 2003, Revell, 2012). In the context of medicinal metabolites, the 
presence/absence of medicinal metabolites can be mapped onto phylogenies and the 
phylogenetic signal can then be measured using Fritz & Purvis’s D metric (Fritz and Purvis, 
2010, Rønsted et al., 2012, Ernst et al., 2016). This enables quantification of whether or not 
the specialised metabolite is significantly phylogenetically conserved.  If it is phylogenetically 
conserved, the metabolite is more-likely to be produced by phylogenetically related taxa. In 
such instances, rather than screening the random group of plants for lead compounds, the 
specific plant clade could be more narrowly targeted and screened using molecular networking 
























A phylogeny for related taxa A, B, C and 
their sister clade G and F, and D and E. 
B is identified as a traditional medicinal 
plant producing medicinal metabolite X 
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identifying the cluster A, B and C all 
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1.5 How to predict medicinal potential for taxa with no metabolomic data 
In many cases, it will not be possible to readily obtain metabolomic profiles for all taxa within 
a plant clade. In such instances where there are missing traits (in this case the metabolites), 
phylogenetic modelling could be used to predict the state (in this case, the presence/absence of 
metabolites) for undescribed taxa. This phylogenetic prediction can be achieved by methods 
such as Phylogenetic Eigenvector Mapping or Phylogenetic Generalised Least Squares and 
Bayesian Inference (Blomberg et al., 2003, Zheng et al., 2009, Guénard et al., 2013, Nunn and 
Zhu, 2014). Hence for a plant clade if the phylogeny is available, and also metabolomic profiles 
for some species are available, it may be possible to predict the traits of a target plant (within 
the known phylogeny) for which metabolomic data are missing. Of the available methods, 
Phylogenetic Eigenvector Mapping is specifically suggested as a useful method for 
pharmaceutical chemistry and ecological predictions (Guénard et al., 2013, Guénard et al., 
2015, Guénard et al., 2017). This approach has been used to predict the generation length of 
at-risk animal taxa by the International Union for the Conservation of Nature (IUCN) for the 
purpose of red list classification (Cooke et al., 2018), where certain species data were not 
available. Using this approach, predictions can be made for species with missing metabolomic 
profiles. This could further streamline the process of predicting medicinal potential of a plant 
or plant group.  
 
1.6 Objective of the current research 
This project uses a combined evolutionary and metabolomics approach to examine medicinal 
potential in the magnoliid clade in Australasia. In the first chapter, an evolutionary perspective 
is provided on how modern advancements in metabolomics can be combined with phylogeny 
to streamline the drug discovery process. In chapter two, metabolomics and chemical 
networking is used to identify chemical similarity across the magnoliids, and also to identify 
species and corresponding metabolites that could be potentially medicinal. In chapter three, 
phylogenetics and metabolomic data are combined to identify whether related taxa produce 
similar metabolites, using phylogenetic signal analysis statistics. In chapter four, phylogenetic 
prediction statistics are used, in order to determine whether presence/absence of metabolites 




metabolomic information of sister clades. A brief summary of the content of each is chapter is 
provided below. 
 
Chapter One: Combining evolutionary inference and metabolomics to identify plants 
with medicinal potential 
Chapter one is a literature review on the current status of plants as a source of medicine. The 
literature survey highlighted current issues in the plant natural product-based drug discovery 
process. The chapter reviews novel, evolutionary and metabolomic approaches that could be 
used in combination to improve the efficiency of plant natural product-based drug discovery.  
 
Chapter Two: Potential medicinal taxa amongst the Australasian magnoliids identified 
using molecular networking 
In chapter two, a metabolomic analysis was conducted on 108 species of Australasian 
magnoliids. The metabolomic similarity across the magnoliids at family level was investigated. 
Molecular networking was also carried out to identify structurally similar metabolites to 
already known medicinal metabolites amongst magnoliids. Based on the findings closely 
related species were identified as chemically more similar. The metabolomic analysis identified 
seven putative metabolites structurally similar to previously characterised bioactive 
compounds, of the magnoliid group. The data gathered in chapter two are used in the 
subsequent chapters to investigate the phylogenetic patterns of medicinal specialised 
metabolites in these magnoliids.  
 
Chapter Three: Phylogenetic signal analysis of secondary metabolomic profiles reveals 
the medicinal potential of magnoliids 
Here I used the metabolomic data obtained in chapter two to investigate the evolutionary 
patterns of metabolite expression. A phylogenetic tree was estimated for the sampled magnoliid 
taxa comprising both known medicinal magnoliids and their related taxa. The metabolomic 




metabolites were measured to understand whether certain metabolites were phylogenetically 
more conserved. Furthermore, the same approach was applied to analogue compound 
molecular network clusters that were identified as having medicinal potential through 
molecular networking. This identified significant phylogenetic signal for 11 metabolites with 
potential medicinal properties, and resulted in the identification of plant genera/families that 
warrant further investigation for medicinal properties. 
 
Chapter Four: Predicting medicinal potential in plants using phylogenetic modelling of 
specialised metabolite expression 
In this chapter, the metabolomic information and phylogeny were used with a phylogenetic 
predictive statistical method, Phylogenetic Eigenvector Mapping (PEM). This was used to 
predict the metabolomic profiles in target taxa. The target taxa are within the known phylogeny, 
with metabolomic profiles for all of the sister taxa available. The PEM approach was over 60% 
accurate for predicting the metabolomic profile of the target taxa. Further, the degree of 
accuracy of prediction was robust to the degree of phylogenetic signal that was observed. 
Therefore, phylogenetic modelling and metabolomic screening would allow prediction of the 
medicinal potential even in the absence of metabolomic data for particular species. 
The metabolomic analysis using molecular networking allowed me to identify potential 
structural analogues of previously described, specialised magnoliid, medicinal metabolites. 
These analogues may harbour similar or different medicinal properties. This approach provides 
target taxa for future investigation through bioassay and structural elucidation to understand 
the real pharmacological properties of analogue compounds. The phylogenetic signal analysis 
revealed clades of importance and the potential metabolites associated with the magnoliid 
clade. Hence, the taxa could be selectively chosen instead of random screening in future 
research for drug candidates. Furthermore this approach could be used more broadly across the 
plant kingdom, in the search for potential medicinal compounds, or in even wider application 




2. CHAPTER ONE  
Combining Evolutionary Inference and Metabolomics to 





















Accepted as:  
Mawalagedera, S. M. U. P., Callahan, D.L, Gaskett, A. C, Rønsted, N., Symonds, M. 
R. E. (2019). Combining evolutionary inference and metabolomics to identify plants 




Combining evolutionary inference and metabolomics to identify plants with 
medicinal potential 
Mawalagedera, S. M. U. P.1, Callahan, D.L 2, Gaskett, A. C 3, Rønsted, N.4, Symonds, 
M. R. E.1 
1 Centre for Integrative Ecology, School of Life and Environmental Sciences, Faculty 
of Science, Engineering and the Built Environment, Deakin University, Burwood, 
Victoria, Australia 
2 School of Life and Environmental Sciences, Faculty of Science, Engineering and the 
Built Environment, Deakin University, Burwood, Victoria, Australia 
3 School of Biological Sciences, University of Auckland, Auckland 1142, New Zealand 
/ Te Kura Mātauranga Koiora, Te Whare Wānanga o Tāmaki Makaurau, Aotearoa 
4 Natural History Museum of Denmark, University of Copenhagen, Copenhagen, 
Denmark 
 
2.1 Abstract  
Plants have been a source of medicines in human cultures for millennia. The past decade 
has seen a decline in plant-derived medicines due to the time-consuming nature of 
screening for biological activity and a narrow focus on individual candidate plant taxa. 
A phylogenetically informed approach can be both more comprehensive in taxonomic 
scope and more systematic, because it allows identification of evolutionary lineages 
with higher incidence of medicinal activity. For these reasons, phylogenetics is being 
increasingly applied to the identification of novel botanic sources of medicinal 
compounds. These biologically active compounds are normally derived from plant 
secondary or specialized metabolites generally produced as induced responses and 
often playing a crucial role in plant defence against herbivores and pathogens. Since 
these compounds are typically bioactive they serendipitously offer potential therapeutic 
properties for humans, resulting in their use by traditional societies and ultimately drug 
lead development by natural product chemists and pharmacologists. The expression of 
these metabolites is likely the result of coevolutionary processes between plants and the 
other species with which they interact and effective metabolites are thus selected upon 
through evolution. Recent research on plant phylogeny coupled with metabolomics, 
which is the comprehensive analysis of metabolite profiles, has identified that related 
taxa produce similar secondary metabolites, although correlations are dependent also 
on environmental factors. Modern mass spectrometry and bioinformatic chemical 




related and potentially new bioactive compounds. The combination of these 
metabolomic approaches with phylogenetic comparative analysis of the expression of 
metabolites across plant taxa could therefore greatly increase our capacity to identify 
taxa for medicinal potential. This review examines the current status of identification 
of new plant sources of medicine and the current limitations of identifying plants as 
drug candidates. It investigates how ethnobotanic knowledge, phylogenetics and novel 
approaches in metabolomics can be partnered to help in characterizing taxa with 
medicinal potential. 


































2.2 Plants as a source of medicine 
Plants have been a perennial source of human therapeutics. The use of plants for 
medicine has been documented as early as 2600 BC (Gurib-Fakim, 2006) and plants 
still play a major role in treating human diseases. People in developing countries rely 
heavily on plant-derived traditional medicines (De Luca et al., 2012), accounting for 
close to 80% of world population (Gurib-Fakim, 2006). In the United States, a 
considerable proportion of approved drugs are derived from plants (9.1% according to 
the USFDA; United States Food and Drug Administration (Newman and Cragg, 2016). 
Furthermore there are many drugs that are modified analogues of plant derived 
secondary metabolites that are in wide use (e.g. aspirin derived from the natural product 
salicin, from the willow tree Salix alba L., codeine and morphine from the opium poppy 
Papaver somniferum L.) (Dias et al., 2012). There are over 28,000 medicinal plants 
recorded in the scientific literature (Allkin, 2017) that are based on knowledge from 
traditional medicine.  
Despite the prevalence of plants in traditional medicine, the majority of plant taxa have 
not received formal experimental appraisal for their medicinal properties. During the 
early twenty-first century there has actually been a decline in the use of plants as a 
source of medicine in the pharmaceutical industry (Atanasov et al., 2015). Of the plant 
species recorded as having therapeutic properties, only 16% have been tested for 
biological activity (Willis, 2017). Furthermore, the pharmaceutical industry more 
commonly uses synthetic chemistry for drug design, even though success in finding 
new leads are limited (Li and Vederas, 2009) and there is a vast diversity of plants with 
biological activity that could be drug candidates. This decline is a result of the 
challenges faced in the conventional plant-based drug discovery process which make 
the overall process time consuming (Figure 2.1). The process starts with identifying the 
species of plant known to have medicinal function, sourcing the plant material, 
obtaining approval according to international legislations such as the convention on 
biological diversity and the Nagoya protocol on access to genetic resources, isolating 
the bioactive compound or compounds, identification of it, and ultimately synthesising 
the candidate compound (Liu and Wang, 2008, Atanasov et al., 2015). For example, in 
the case of the drug artesunate derived from artemisinin originally discovered from 




identification and production of the candidate drug. The time delay was due to the six 
month Artemisia cultivation period followed by the bioactive compound purification 
period (Wells et al., 2015). This was prior to the longer process of bio assaying, and 
before clinical testing. In addition to these practical issues, identifying the biologically 
active compounds from the plant source is challenging due to the enormous chemical 
diversity of plants and possibility of synergistic effects among compounds (Kingston, 
2011). Furthermore, elucidating the mechanism of action of plant-based drugs also 
remains a slow process. These are only the delays after a plant source has been 
identified, and do not consider the time taken to identify that original botanic source in 
the first place. Overall this process of screening plant taxa for biological activity is 







Figure 2.1: Conventional pathway from random screening to novel drugs, using Taxus 
brevifolia Nutt. and alternative partially synthetic pathway from Taxus baccata L. as 
example species, a process which took over 30 years.  
Based on information from: (Wani et al., 1971, Holton et al., 1994, Wall and Wani, 
1995, Baloglu and Kingston, 1999, Weaver, 2014)  
Random screening of plants 
1960
1. Taxonomic identification-




















Taxus baccata L.  
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4. Chemical structural elucidation;
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The study of therapeutic traditional use of plants is a multidisciplinary area, because 
both pharmacology of the plant and human behaviour has affected whether and how the 
plant is used. As an example in traditional medicine there are many instances where 
complex herbal mixtures are used (Leonti and Casu, 2013). In such instances the 
metabolites in the herbal mixture may need to act in synergy to yield the 
pharmacological effects (Wagner, 2011). Further, some plant-based traditional 
medicines may also have different preparation methods. Based on the preparation 
methods the mode of action of the medicinal metabolites may differ (Heinrich et al., 
2009). In addition to that some traditional communities may also select plants based on 
specific traits (De Medeiros et al., 2015). Therefore consideration should be given to 
all of these related processes in ethnopharmacological studies. Despite these 
complications, ethnopharmacology still does provide a credible starting point in 
narrowing the target taxa for natural product chemistry research.   
There are also significant challenges for managing how ethnopharmacological 
knowledge is partnered with scientific discovery methods and the pharmaceutical 
industry. Cultural appropriation and exploitation of traditional knowledge is a serious 
and ongoing issue given that intellectual property is often regulated by researchers and 
pharmaceutical companies (Mcgonigle, 2016). Thus a mechanism to acknowledge the 
indigenous knowledge of ethnobotany also needs to be adopted in drug discovery 
(Gupta et al., 2005). The International Platform on Biodiversity and Ecosystem 
Services (IPBES) established in 2012, acknowledges by developing and governing a 
set of principles that recognizes the contribution and knowledge of indigenous and local 
cultures in the use of biodiversity (Pert et al., 2015). Thus the use of a proper legal 
framework and collaborations of indigenous communities, scientist and policymakers 
may also greatly help in sharing and utilizing the wealth of ethnopharmacological 
knowledge (Shane, 2004).  
Largely in the pharmaceutical industry, drug discovery novelties are few and the need 
for bioactive compounds are persisting. Given the lengthy process of sampling, 
screening and biological testing, many plants are not investigated. Despite evidence that 
plants are a rich source of bioactive compounds. Hence the need for alternative 




required. Novel approaches for  identifying medicinal plant taxa more effectively need 
to be explored (Liu and Wang, 2008). 
Recent advancements in the screening processes for natural products are stimulating 
renewed effort in plant-based drug discovery. Most notably, the 2015 Nobel Prize for 
medicine was awarded for identifying an antimalarial compound from Artemisia annua 
L. using the knowledge of traditional Chinese medicine (Tu, 2011). Currently the two 
main drugs used to treat malaria are plant derived (artemisinin and quinine from 
Cinchona L. barks) highlighting that plant-derived pharmaceuticals are highly relevant 
for drug discovery. Furthermore during the last decade, several new plant-derived drugs 
(apomorphine hydrochloride; water lily (Nymphaea L. sp), galanthamine 
hydrobromide; snowdrop (Galanthus nivalis L.), nitisinone; bottlebrush plant 
(Callistemon citrinus Curtis.), tiotropium bromide; devil’s snare (Datura stramonium 
L.) and Cytisine; golden rain acacia (Cytisus laborinum L.) have been approved by the 
USFDA (Das, 2017) (Auffret et al., 2018). According to World Bank projections, a 
growth rate of 5-15% annually in the plant-based medicinal market is anticipated (Liu 
and Wang, 2008). Thus identifying biologically active potential medicinal plant sources 
is currently a commercially viable and beneficial research area, albeit one with 
significant cultural issues. 
 
2.3 Role of plant secondary/ specialized metabolites in treating diseases 
A medicinal plant is defined as a botanical source able to cure, prevent or relieve a 
disease, or a plant that is utilised as a drug or a precursor for a drug (Rates, 2001). Most 
of the active components of newly developed drugs are plant secondary metabolites 
(Balunas and Kinghorn, 2005). Plant secondary metabolites are compounds that are not 
directly responsible for plant growth and development, instead they are the products of 
specific sets of enzymatic reactions broadly known as metabolic reactions (Hartmann, 
2007). Many plant secondary metabolites serve as defensive compounds produced to 
overcome the challenges plants face in the environment, including pathogens and 
herbivores but also abiotic stressors (Wink, 1988). In addition, some of these secondary 
metabolites also serve as allelopathic defensive compounds, synthesised in response to 




chemical entities are specialised /secondary metabolites, which are typically expressed 
systemically, but occasionally the expression of these secondary metabolites is 
localised.  
Plant secondary metabolites are structurally specialised by having highly active 
functional groups (i.e. aldehyde, sulfhydryl groups, epoxides, hydroxyl, and carbonyl 
groups) to act on cellular targets, such as enzymes, cell receptors and transporters. 
Therefore, when a medicinal plant product is ingested by humans, the secondary 
metabolites mediate a chain of reactions that may be beneficial in treating diseases 
(Acamovic and Brooker, 2005, Wink, 2015). As a result of their effect on the biological 
systems of hosts, secondary metabolites exhibit major properties as for example 
antiviral, antimicrobial, antifungal, antimalarial, analgesic, antiarrhythmic, 
antihypertensive, psychoactive and tumour inhibition agents. However, out of 
c.100,000 known bioactive secondary metabolites, remarkably few have been 
scientifically screened for their activity (Wink, 2015).  
The biggest challenge is identifying the target bioactive compound from the plant 
material, since every crude plant extract contains thousands of compounds, most of 
which are unknown (Atanasov et al., 2015). Thus identification of biologically active 
compounds is done through comparing the chemical structures of compounds identified 
from the plant, to those already existing in compound libraries typically used in 
analytical processes (i.e. mass spectrometry (MS) and nuclear magnetic spectroscopy 
(NMR) (Dias et al., 2016). Examples of these include KNApSAcK (Afendi et al., 
2012), the Universal Natural Product Database (UNDP) which is an open source library 
with bioactivity information,  the Global Natural Product Database (GNPS) and 
Massbank (Johnson and Lange, 2015). However,  these libraries do not include all the 
natural products that plants produce (Schwager et al., 2008). Furthermore, inevitably if 
searching for new candidate drugs, many plant compounds are likely to be new to 
science (Takeuchi et al., 2018), and hence not present in compound libraries. Therefore, 
studies providing broad identification of the secondary metabolites with biological 
activity from plants, can provide an enormous amount of information applicable to the 





2.4 Identifying therapeutic plants across the plant kingdom  
Known medicinal activity is not randomly distributed across the plant kingdom. There 
are specific distribution patterns where certain lineages are significantly more bioactive 
(Coley et al., 2003). This pattern is also reflected in the traditional use of plants by 
humans. Different cultures around the world tend to use related plant taxa for similar 
medicinal purposes (Saslis-Lagoudakis et al., 2011a). This ethnobotanical convergence 
suggests that therapeutic potential may have phylogenetic constraints (Zhu et al., 2011, 
Yessoufou et al., 2015, Garnatje et al., 2017). Therefore by investigating 
ethnopharmacological use of plants, phylogenetically related target species for further 
investigation could be identified.  
Phylogenetic exploration of approved drugs of natural origin has identified eleven 
major plant clades that have delivered the significant part of these approved drugs (Zhu 
et al., 2011). Likewise, there is evidence of particular plant lineages expressing specific 
secondary metabolites with medicinal function (Rønsted et al., 2012). For example, in-
depth studies of the synthesis of the secondary metabolites of terpene structure reveal 
that there are seven groups of gene families responsible for terpene synthesis. These 
genes are specific to plant lineages (land plants, vascular plants, gymnosperms) and the 
types of terpenes they synthesise varies respectively between clades (Feng et al., 2011). 
Thus, a broader understanding of how the genes responsible for secondary metabolism 
have evolved across plant taxa will provide information on the type of secondary 
metabolites synthesised by a plant lineage.  
Secondary metabolites can be either ubiquitous or expressed in specific plant lineages 
(Chezem and Clay, 2016). Since secondary metabolites confer survival benefits to 
plants, they are under natural selection (Wink, 2003). The genes responsible for plant 
secondary metabolism are versatile and have high plasticity to adapt to environmental 
pressures. In contrast, the genes responsible for primary metabolism are stringent and 
expression is generally relatively inflexible (Hartmann, 2007). Genes responsible for 
secondary metabolism therefore have the ability to be upregulated and downregulated 
across lineages in response to selection imposed by the other species with which they 
interact (e.g. herbivorous insects) or environmental stress factors. This presents extra 
challenges to drug discovery as environmental factors can also play a role in the amount 




Differential gene expression is responsible for the lineage specificity of secondary 
metabolites. For example, in Arabidopsis thaliana (L.) Heynh. and other closely related 
Brassicaceae plants, glucosinolate expression is controlled by the 
methylthioalkylmalate (MAM) synthases gene cluster (Benderoth et al., 2006). Studies 
of differential expression of MAM genes have shown that positive natural selection has 
shaped the synthesis of glucosinolates as a defence mechanism to insect herbivory 
(Benderoth et al., 2006, Figueiredo et al., 2008). The phylogenetic history of 
Arabidopsis and its close relatives reveals specific gene duplication points, where new 
MAM genes were positively selected for the combinations of glucosinolates that those 
genes encoded (Benderoth et al., 2006). Synthesis of many plant secondary metabolites 
is regulated by different gene families, and they could have similar underlying gene 
duplication and selection histories explaining their diversity.  
Differential gene expression in secondary metabolism is also driven by coevolution - 
the correlated evolution between two groups of ecologically interacting organisms, 
resulting in reciprocal evolution of both groups in response to each other (Ehrlich and 
Raven, 1964). Coevolution-mediated expression of secondary metabolites has been a 
major hypothesis in understanding the differential expression of secondary metabolites 
across plant lineages (Speed et al., 2015). One of the best studied models of coevolution 
concerns the chemical diversity of the family Apiaceae (which includes such well-
known plants as dill; Anethum graveolens L., coriander; Coriandrum sativum L., 
cumin; Cuminum cyminum L. and fennel; Foeniculum vulgare Mill.). The coevolution 
of the Apiaceae and Papilio butterflies is reflected in their shared patterns of phylogeny 
where chemical shifts in the phylogeny of the butterflies has governed host plant 
diversifications (Berenbaum, 2001,, Berenbaum and Zangerl, 2008). Several other well 
documented examples of reciprocal adaptations between host plants and their specialist 
herbivores include Barbarea vulgaris (Aiton) (rocketcress; Brassicaceae) and 
Phyllotreta nemorum L. (turnip flea beetle), Brassicales plants and Pierinae butterflies, 
and Pastinaca sativa L. (Parsnips; Apiaceae) and Depressaria pastinacella 
(Duponchel) (Parsnip webworm) (Zangerl et al., 2003, Toju and Sota, 2006, Agrawal 
et al., 2012b, Edger et al., 2015).  
Plant secondary metabolite expression can also be driven by generalised, rather than 




Burseraceae) showed that secondary metabolites able to act as herbivore repellents were 
found frequently in high abundances in Protieae tribe plants, even in the absence of 
specialised herbivores. This suggests that regardless of the type of herbivore, the mere 
existence of any natural enemy can affect how secondary metabolites are expressed in 
plants (Salazar et al., 2018). Conversely, Oenothera biennis L. (common evening-
primrose) populations grown in controlled insect pest-free environments, had reduced 
defences against insects pests over time, i.e. they reduced their production of toxic 
secondary metabolite in response to decreased herbivory (Agrawal et al., 2012a).  
Some of the chemical drivers behind the expression of these secondary metabolites are 
herbivore-associated elicitors (metabolites released into the plant by the herbivores).  
Many of these elicitors are produced by insects, and range from enzymes and modified 
lipids to sulphur containing fatty acids (Bonaventure et al., 2011). These elicitors have 
the ability to stimulate biosynthetic pathways within a plant (Waterman et al., 2019). 
Further, the action of these elicitors tends to be associated with certain plant-insect 
associations. For example the lepidopteran Manduca sexta L. (tobacco hornworm) 
releases fatty acid‐amino acid conjugates into the plant that stimulate the biosynthesis 
of jasmonic acid in Nicotiana attenuata Torr. ex S.Watson (wild tobacco) (Wu et al., 
2007, Meldau et al., 2011). Jasmonic acid afterwards mediates the synthesis of 
secondary metabolites as defence compounds in N. attenuata (Kallenbach et al., 2010). 
Thus, expression of secondary metabolites is governed both by evolution (i.e. one-way 
adaptation in response to generalised herbivory) and coevolution (i.e. specific 
reciprocal adaptation between the interacting host and a herbivore species) (Caseys et 
al., 2015). 
Overall, the genetic mediation of plant secondary metabolite expression does not act in 
isolation. There are abiotic factors such as temperature, soil pH, and frost exposure that 
may have effects on overall plant secondary metabolism. In Zea mays L. (corn) changes 
in abiotic factors as soil humidity, temperature and light had significant effects on the 
volatile secondary metabolite production (Gouinguené and Turlings, 2002). These 
environmental stressors are also correlated with the abundance of natural enemies or 
herbivores and plant pathogens which themselves affect the expression of secondary 
metabolites (Müller and Orians, 2018). Therefore studying secondary metabolite 




relevant method to understand differential gene expression, and thus the distribution 
and occurrence of plant secondary metabolites. This has theoretical implications for the 
tracking the expression of traits according to phylogeny, as well as for medicinal and 
drug discovery.  
 
2.5 Use of phylogeny and metabolomics to identify biological activity in plants 
Understanding how secondary metabolite gene expression varies across clades is a 
potential key to identifying biologically active plants. For example, the kinds of 
enzyme-encoding gene clusters used by algae and mosses are distinctively different 
from those found in grasses and eudicots (Chae et al., 2014). Furthermore, analysis of 
the metabolomic reactions within these plant groups has shown that closely-related taxa 
express the same set of reactions, thus suggesting phylogenetic constraints on 
secondary metabolite expression. If true, in depth analysis of plant secondary 
metabolite evolution would help us to understand which taxa/clades are biologically 
active, and hence are good candidates as medicinal species. In other words, the 
phylogenetic patterns of secondary metabolite expression could potentially act as a 
marker for biological activity, and therefore potential medicinal use.  
There have been numerous studies in the past decade describing phylogenetic patterns 
of secondary metabolite expression (Rønsted et al., 2008, Saslis-Lagoudakis et al., 
2011a, Rønsted et al., 2012, Saslis-Lagoudakis et al., 2012, Saslis-Lagoudakis et al., 
2015, Ernst et al., 2016, Guzman and Molina, 2018). Analysis of volatile terpenes from 
angiosperm taxa has shown phylogenetically conserved expression, with related species 
producing the same terpenoid across the phylogeny. In particular, species belonging to 
the Magnoliid clade such as orders Laurales, Magnoliales had very high terpene 
diversity (Courtois et al., 2016). This suggests that the origin of the Magnoliids 122-
125 million years ago is a key evolutionary point at which plant volatile terpene 
synthesis increased significantly. The Magnoliids are also one of the eleven clades 
predicted to have significantly higher pharmacological activity (Zhu et al., 2011). 
Indeed, over a quarter (18 families) of the 66 drug productive families identified, are 
from the Magnoliid clade (Zhu et al., 2011). Other lineages with high degrees of 




plus angiosperms from the monocots (Commelinids, and orders Asparagales and 
Liliales), the basal or early diverging eudicots (Ranunculales) and more derived 
eudicots (Fabids and Malvids from the Rosids, and Lamiids and Campanuliids from the 
Asterids) (Zhu et al., 2011); APG IV 2016). Phylogenetic patterns in bioactivity 
(through secondary metabolite expression) have also been examined at the genus level 
for the angiosperms Euphorbia (Euphorbiaceae; Rosid) and Narcissus 
(Amaryllidaceae; Asparagales) with both genera yielding significant phylogenetic 
signals in biologically active secondary metabolite expression (Rønsted et al., 2008, 
Ernst et al., 2016). 
The strong patterns of phylogenetically conserved expression of secondary metabolites 
could underlie the observed ethnobotanical convergence, in which similar plant taxa are 
used in similar ways in different parts of the world. Research on cross cultural patterns 
of medicinal plant usage reports the use of taxa from the same clades, across continents 
to treat similar diseases, signifying that there is phylogenetically non-random selection 
of therapeutic plants by indigenous cultures (Saslis-Lagoudakis et al., 2011a, Saslis-
Lagoudakis et al., 2012). As an example, there are accounts for using Piper umbellatum 
L. (cow foot leaf; Piperaceae, Magnoliid) to treat kidney and digestive diseases across 
North America, Africa and South East Asia (Roersch, 2010). Further cross-cultural 
patterns have been revealed in a larger study across a number of genera e.g. Aloe Aloe 
vera (L.) Burm. f. (Asphodelaceae; Asparagales), the breadfruit Artocarpus altilis 
(Parkinson) Fosberg (Moraceae; Rosid), Papaw Carica papaya L. (Caricaceae; 
Brassicales) and love vine Cassytha filiformis L. (Lauraceae, Magnoliid) used for 
medicinal preparations across the Caribbean Islands (Halberstein, 2005). Thus 
information from traditional medicine, along with biological active metabolite 
expression, coupled with phylogeny could be the strategy for next generation drug 
productive taxa identification. 
Recent research has used phylogenetic approaches to predict medicinal potential of 
plants. For example, phylogenetic mapping was performed for plant species with 
compounds used for treating cardiovascular disease, based on ethnobotanic and 
pharmacological mode of action of the drug. Seven angiosperm plant families were 
identified as having similar pharmacology: Zingiberaceae (Commelinid monocot), 




(Asteriids). Those families have been suggested as potential target clades for 
identifying novel leads in treating cardiovascular diseases (Guzman and Molina, 2018). 
Despite these promising advances, research to date has not specifically quantified the 
capacity of phylogeny to predict medicinal potential in specific lineages. This can be 
done by measuring the phylogenetic signal of a trait (Münkemüller et al., 2012), in this 
case, biological activity, across a large clade of plants with a high frequency of reported 
traditional medicinal use.  
Phylogenetic signal reflects the tendency of closely-related species to be phenotypically 
similar in contrast to species drawn at random from the same phylogeny (Blomberg et 
al., 2003). It can be measured via a number of metrics for data that are continuous 
(quantitative) or discrete (e.g. presence/absence data) (Fritz and Purvis, 2010, 
Münkemüller et al., 2012, Kamilar and Cooper, 2013). In a medicinal use context, Fritz 
and Purvis’s (2010) D statistic has been used to compare the phylogenetic distribution 
of presence/absence of both therapeutic use and expression of particular compounds 
across plant species, and whether this conforms to either a random distribution (with no 
phylogenetic signal) or distribution that would be expected if the trait had evolved by 
Brownian motion (gradual divergent evolution) (Saslis-Lagoudakis et al., 2015). This 
has been used to identify a phylogenetic signal of medicinal potential in the family 
Amaryllidaceae in relation to alkaloid diversity, where five of seven alkaloid groups 
exhibited weak, but significant, phylogenetic signal (Rønsted et al., 2012). The D 
statistic was also used to map the phylogenetic signal in leaf succulence and medicinal 
use across the genus Aloe finding that a succulent leaf habit is associated with the 
potential of a species to be used as a medicine (Grace et al., 2015).  Furthermore the D 
statistic has also been used to predict presence of artemisinin and antimalarial properties 
in other Artemisia (other than Artemisia annua L. (Pellicer et al., 2018). 
 
2.6 Using phylogenetic trait mapping and molecular networking to predict 
medicinal potential 
Novel techniques of metabolomics such as molecular networking can be used to 
identify metabolites that are structurally similar to already known bioactive metabolites 
(Allard et al., 2016). In molecular networking the fragmentation pattern of a metabolite 




compounds and similar metabolites are identified based on the structure (Figure 2.2). 
These are then put into network clusters, where a single cluster would therefore refer to 
a single metabolite group that likely share many similar chemical (and hence potentially 
bioactive) properties. Therefore this technique allows one to identify groups of 
potentially bioactive metabolites, and novel compounds with such properties. Further, 
by treating such networks as phenotypic characters, one can map their expression onto 
phylogenies and identify clades with related bioactive properties in a way that does not 
rely specifically on the identification of single compounds.  
Tandem mass spectrometry-MS/MS based molecular networking has been extremely 
informative in chemical similarity studies identifying related chemical entities across 
taxa/clades. Once the chemical entities are identified using Global Natural Product 
Social Molecular Networking (GNPS), it is possible to identify which taxa share the 
same molecular network cluster. Furthermore, MS/MS spectra can be related to 
biosynthetic pathways and their biological activity using online databases for natural 
products, thus providing information on the medicinal potential of a taxon. One 
limitation with this approach is that it requires some pre-existing knowledge of 
chemical compounds’ biological activity to identify analogues with similar potential. It 
may not be so effective in identifying novel biologically active compounds that have 



















Figure 2.2: Hypothetical molecular network for three compounds eluting at different 
retention times, with different parent masses (left, indicated from the MS parental ion 
spectra in yellow, blue and magenta) – but with similar MS/MS fragment ion spectra, 
right (A), (B) and (C). 
 
The similarity score is calculated for the MS/MS fragmentation patterns based on 
number of peaks that are similar across A, B and C. 
 
1 is a single peak difference between A and B (highlighted in green) - the similarity 
score of yellow and blue MS/MS fragment spectra is 0.9 
 
2 a single peak difference between B and C (highlighted in green) - the similarity score 
of blue and magenta MS/MS fragment spectra is also 0.9 
 
1 and 2 combined are two peaks difference between A and C - the similarity score of 
yellow and magenta MS/MS fragment spectra is therefore somewhat less = 0.8 
 
The molecular network is generated by calculating the similarity score between yellow, 
blue and magenta compounds (parent ions – the nodes in the network) based on the 
MS/MS fragmentation (C), (B) and (A). The connecting lines (edges) gives the 
similarity score. Threshold values of similarity can be set to determine presence within 
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There have been numerous studies identifying novel bioactive candidate compounds 
using molecular networking in species such as in the Euphorbiaceae species Euphorbia 
dendroides L. (tree spurge) and Codiaeum peltatum (Labill.) P.S.Green (croton), and 
identifying chemicals of cannabinomimetic activity from the cyanobacteria genus 
Moorea (Kleigrewe et al., 2015, Nothias et al., 2018, Olivon et al., 2018). However, 
the focus of these studies was on single taxa without considering their evolutionary 
history. Multi-species studies do exist, as in the recent study of acetylcholinesterase 
inhibitors produced by a range of Iranian monocot and eudicot flowering plant taxa, 
where new compounds as well as taxa responsible for expressing the new compounds 
were identified (Abbas-Mohammadi et al., 2018), but again the study taxa here were 
restricted only to known medicinal species, with little consideration of phylogenetic 
relatedness except in few recent research concerning Euphorbiaceae (Ernst et al., 2018). 
However, with the existence of phylogenetic and metabolomic information across 
multiple species, this approach could be further scaled up to comprising taxa with 
ethnobotanic medicinal use as well as their sister taxa for which no known records of 
ethnobotanical medicinal use exist, to identify target taxa for medicinal potential (see 
Figure 2.3). 
In summary, the combination of ethnobotanic information, phylogeny and molecular 
networking provides a promising approach to plant natural product-based drug 
discovery. By investigating the metabolomics profiles, of a target highly bioactive plant 
clade comprising both known medicinal and understudied taxa, chemically related taxa 
could be identified via molecular networking. The phylogenetic signal of those 
chemical compounds (or chemical networks) could be quantitatively measured by 
constructing the phylogeny and using phylogenetic signal-measuring statistical 
methods. This will allow prediction of the medicinal potential of previously 
understudied taxa. Combining these approaches holds a key to the advancement of plant 



































Figure 2.3: Proposed integrated approach for identifying potentially medicinal plant taxa using 
metabolomic profiles of species A, B, C and D (phylogenetically closely related species belonging to 
same operational taxonomic unit/ family) and species P, Q and R (likewise but from a different 
operational taxonomic unit/ family) 
  
Note* In the molecular network the nodes are further divided in to pie charts to represent the taxa sharing 
a particular metabolite. The area corresponds to the parent ion intensities in each node produced by 
respective taxa. The colour code of the nodes correspond to the colour code on the metabolites table and 
the phylogeny for ease of understanding the figure.  
A)  
Taxa Secondary metabolite  




P Y, Y1 
Q  Y 
R  
 - known traditional medicinal taxa  
 - taxa with no identified secondary metabolite profiles  
X - known bioactive secondary metabolite 
Y - known bioactive secondary metabolite  
X1, X2 - metabolites structurally similar to X 










       
        
  
      
       
        
       
Figure 2.3 (A) Hypothetical secondary 
metabolites identified using UHPLC-
MS/MS in respect to taxa A, B, C, D, P 
and Q. Only taxa A and Q have 
previously known traditional medicinal 
uses. Taxa A and Q express the already 
identified bioactive metabolites X and Y 
respectively.  
 
Taxon D is phylogenetically closely 
related to taxa A, B and C. It does not 
have any known medicinal properties or 
identified bioactive metabolites. Taxon R 
is phylogenetically closely related to taxa 
P and Q. It does not have known 
medicinal properties or identified 
bioactive metabolites 
  
  Molecular phylogeny of taxa A, B, C, D, P, Q, R, L, M.  
 B and  R taxa is potentially medicinal due to close 
phylogenetic relationship respectively with  A and  Q; 
traditional medicinal taxa 
Molecular phylogeny of taxa  A, B, C, D, P, Q, R, L, M. 
with the molecular network information pointing out taxa 
 C,  D,  P are also potentially medicinal based on 
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Figure 2.3 (B) Hypothetical GNPS based molecular network* and the molecular phylogeny of the 
corresponding taxa 
 
 - Potentially medicinal taxa. These taxa could be identified by looking at the molecular network 
cluster patters and the phylogenetic relationships of the target taxa D and R for which there are no 
previous records of metabolomic profiles. Given that their respective locations in relation to taxa A, 
B, C, P and Q, statistical inferences could be used to predict the medicinal potential based on 






3. CHAPTER TWO 
Potential medicinal taxa amongst the Australasian 
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3.1 Abstract  
Drug discovery from plants remains an important source of new medicines. The 
pharmaceutical industry and academic researchers utilise knowledge of traditional 
medicine, as well as arbitrary screening of plants, to identify lead compounds for drug 
development. This process is lengthy and complex, therefore there is a need for a more 
effective approach to identify plants with medicinal potential. Modern mass 
spectrometry allows the coupling of ultra-high resolution and accurate mass data with 
collision-induced dissociation allowing thousands of MS and MS/MS spectra to be 
collected rapidly from crude plant extracts. These data can be integrated using 
molecular networking to search for structurally related bioactive compounds. I utilised 
this approach to investigate potentially useful taxa in the economically important 
magnoliid plant orders. Leaf samples were screened using ultra high-pressure liquid 
chromatography coupled to an orbitrap mass spectrometer. A molecular network for 
108 Australasian magnoliid species was then produced to determine the chemical 
similarity across taxa. The overall chemical profile similarity analysis suggested that 
the related species were chemically more similar to each other. Seven putative 
metabolites structurally similar to previously characterised bioactive compounds 




piperoleine), and respective magnoliid families previously not recorded for the 
expression of those metabolites were identified. This work shows that metabolomic 
analysis coupled with molecular networking is a powerful approach for the 
identification of new potentially medicinal taxa, and emphasises the value of the 
Magnoliids as medicinally important clade of plants.  






















Natural products are one of the major sources of drug leads in pharmaceutical industry. 
These compounds are widely extracted from either plants, animals, or microorganisms 
(Brusotti et al., 2014, David et al., 2015). Plants in particular have a long history of 
medicinal use and as a source of therapeutic natural products (Newman and Cragg, 
2012, Atanasov et al., 2015, Weyrich et al., 2017). These therapeutic natural products 
are so-called secondary or specialised metabolites and have evolved in response to 
biotic and abiotic stressors (David et al., 2015).  Often when exploring plant sources 
for therapeutic specialised metabolites, it has been evident that related taxa yield similar 
specialised metabolites. As an example related Taxus L. species have provided leads 
for anticancer drugs, related Salix L. species have provided salicylate leads for aspirin, 
related Artemisia L. species have provided the antimalarial artemisinin and related 
Ephendra L. species have provided ephendrine alkaloids (Mahdi, 2010, Malik et al., 
2011, Ibragic and Sofić, 2015). These specialised metabolites are often defence 
compounds that express their effect through mediating neuroreceptors, enzymes, ion 
channels, ion pumps and other mechanisms of action in both insects, animals and 
humans (Wink, 2015). 
There are >28,000 plant species recorded as having therapeutic properties. Only about 
16% of that has been studied. Overall there is estimated c. 400,000 flowering plants in 
the world with the majority uninvestigated for medicinal potential (Willis, 2017). In the 
past, the screening of plants for bioactive compounds was either based on 
ethnopharmacology or was largely arbitrary. This was followed by the arduous process 
of refining the bioactive compounds to provide single molecule drugs, which could be 
used for their therapeutic properties. Due to the complexity and the diversity of 
bioactive natural products the screening process was inefficient, leading to a decline in 
the use of plants for source of new drug candidates despite their obvious potential 
(David et al., 2015). One of the major limitations of natural product drug discovery is 
the ambiguity in metabolite identification from crude plant extracts (Allard et al., 2016). 
With the introduction of new metabolomic methods and advancements in mass 
spectrometry, identification of bioactive natural products from plants could be made 




Advances in mass spectrometry have vastly increased the number of molecules that can 
be detected in plant crude extracts. Metabolomic analysis provides a powerful technique 
for comparing the natural product profiles of plants (Cox et al., 2014). For example, 
this approach was recently used to study the antimicrobial secondary metabolite profiles 
across taxa found in agricultural grasslands, including several legumes, and showed that 
closely related taxa have similar metabolomic profiles (French et al., 2018). Likewise, 
untargeted metabolomic analysis has been used to identify potential medicinal plants 
for lead compound development (Shyur and Yang, 2008). For example, identification 
of a new flavanone from Monotes engleri Gilg (family Dipterocarpaceae) was based on 
novel methods of metabolomics (Wolfender et al., 2000). Ultra-high performance 
liquid chromatography coupled to high-resolution tandem mass spectrometry (LC-
HRMS/MS) is particularly suited for screening natural products. Also, the use of the 
soft ionisation technique of electrospray ionisation facilitates the detection of intact 
structurally diverse molecules (Lanzotti and Osbourn, 2009, Sawada and Hirai, 2013). 
Analyses of crude plant extracts can routinely detect more than 10,000 compounds per 
sample with this approach. Furthermore the fast scan speeds, fast MS/MS, accurate 
mass and high resolution enables acquisition of high quality data, enabling putative 
structural identifications (Commisso et al., 2013). However, these large and complex 
datasets require new data processing tools to mine the chemical diversity. Molecular 
networking has the ability to carry out de-replication of already known bioactive 
compounds from these complex datasets and discover new structurally related 
metabolites from already known bioactive compounds (Yang et al., 2013).  
Molecular networking is the representation of relationships between tandem mass 
spectral (MS/MS) data in the form of networks. This approach uses data from a form 
of untargeted MS/MS where precursor ions are selected based on a simple criterion 
such as abundance. The selected precursor ions are then subjected to MS/MS. Modern 
high resolution instrumentation can carry out at least 10 MS/MS scans per second 
resulting in thousands of MS/MS spectra collected in a relatively short (10-15 min) 
analysis. Molecular networking relies on the assumption that key structural components 
will be detected in the MS/MS spectra of similar molecules due to similarities in the 
overall structure, stability of daughter ions and presence of similar key functional 
groups (Yang et al., 2013). Therefore, by comparing the MS/MS fragmentation pattern, 




Natural Product Social Molecular Network (GNPS) is an online repository, which 
allows the analysis of MS/MS data to obtain molecular networks and structural 
identifications of unknown chemical entities in natural samples (Wang et al., 2016). 
The output from GNPS provides a molecular network with MS/MS spectra represented 
in nodes and the relationship between the MS/MS spectra of a single node with the 
adjacent node as edges with a similarity score (Yang et al., 2013). Each of the molecular 
network clusters thus contains parent ion nodes, which are produced by similar 
metabolites (Chapter one, Figure 2.2).  
The use of GNPS molecular networking has gained momentum in recent years in the 
exploration of chemical diversity across biological samples (Allard et al., 2016, Cabral 
et al., 2016, Naman et al., 2017). For example, research on marine actinomycetes, 
bacteria, cyanobacteria and algae successfully applied GNPS based molecular 
networking to identify chemical similarities and strain specific expression of 
metabolites with interesting biological activity (Jensen et al., 2007, Nguyen et al., 2013, 
Liu et al., 2014b, Luzzatto-Knaan et al., 2017). This approach has also been extended 
to the plant kingdom to identify sample specific secondary metabolites from 
Euphorbiaceae taxa (Allard et al., 2016, Ernst et al., 2018, Olivon et al., 2018). Yet 
there have been no attempts to characterise the chemical similarity across a larger group 
of angiosperms using molecular networking as the first step to identifying potentially 
medicinally useful plant taxa.  
Here we describe a study on the chemical similarity/diversity from an ancient 
angiosperm clade (Australasian magnoliids), famous as both a spice and a medicinal 
group (Lassak and Mccarthy, 2011), using molecular networking. The magnoliids are 
one of 11 major plant clades, which have given rise to significantly higher numbers of 
drugs of natural origin (Zhu et al., 2011). The magnoliid family Annonaceae alone 
comprise close to 11.9% of medicinal species, in comparisons to well-known medicinal 
families as Euphorbiaceae which comprise close to 13.5% recorded medicinal species 
(Willis, 2017). At this stage there has been no in-depth analysis of the chemical 
diversity of this clade or its potential to provide new drug leads. In Australia and New 
Zealand there are c. 350 species of magnoliids, belonging to four different Orders 
(Magnoliales, Piperales, Laurales and Canellales) (Wilson, 2007). Australasian 




medicines, such as mountain pepper (Tasmannia lanceolata (Poir.) A.C.Sm. of 
Winteraceae) and kawakawa (Piper excelsum (G.Forst.) Miq. of  Piperaceae), yet many 
of the magnoliid species chemical diversity are largely unexplored (Breitwieser et al., 
2010, Lassak and Mccarthy, 2011). Through metabolomic analysis of plant secondary 
metabolite profiles, medicinally important compounds and the taxa expressing those 
compounds can be identified. The key aims of this research were to i) investigate 
whether related taxa produce similar metabolites and ii) identify novel potential leads 
from known magnoliid bioactive compounds using molecular networking.  
 
3.3 Materials and Methods 
A complete summary of workflow and the software used is given in Figure 3.1.  
 
3.3.1 Sample collection 
Magnoliid leaf samples were harvested for 108 species accounting for close to one third 
of Australasian magnoliid diversity with emphasis on already identified medicinal 
magnoliids, their availability in arboreta, and being proportionally representational of 
the actual taxonomic diversity (10% Atherospermataceae, 3% Hernandiaceae, 58% 
Lauraceae, 12% Monimiaceae, 3% Myristicaceae, 12% Piperaceae and 8% 
Winteraceae from an actual diversity of 5% Atherospermataceae, 2% Hernandiaceae, 
67% Lauraceae, 6% Monimiaceae, 3% Myristicaceae, 8%, Piperaceae and 8% 
Winteraceae) during the summers of 2015, 2016 and 2017, from arboreta in Australia 
and New Zealand (Appendix A-Supplementary Material-Table 6.1). Each species had 
2-7 replicates collected, based on their availability in the collections. Two young leaves 
were selected from each plant and they were stored in zipper seal bags with label tags 
and were transferred to laboratory frozen in insulated containers. They were then freeze 





3.3.2 Sample preparation 
After storage at -80°C, the samples were frozen in liquid nitrogen and homogenized to 
a fine powder using a liquid nitrogen cooled mortar and pestle. The homogenized leaf 
powder was kept frozen and 50 mg was weighed into 2 mL Eppendorf tubes. 
Approximately 1/4 of volume homogenising silica beads (Sigma-Aldrich) were added 
to tubes followed by the addition of 300 µL of an extraction solution comprising 2:3:3 
water:acetonitrile:isopropanol with 20 µM internal standard (Foroughi et al., 2014). 
Solvents were all HPLC grade. Samples were then placed in a cooled Retsch mill 
(Retsch laboratory equipment) and extracted at 30 Hz for 2 min. Following extraction, 
tubes were centrifuged at 14,000 rpm and supernatant transferred to 2 mL HPLC vials. 
A pooled biological quality control sample (PBQC) was also prepared by combining 5 
µL aliquots of each extract. Extracts were stored at -80°C until analysis. Standard 
solutions containing 10 µM of the following compounds: piperine, quercetin and 
polygodial were also prepared and analysed. These standard compounds except for 
caffeine (which was chosen on the basis of being absent in magnoliids and being a 
widely used standard metabolite in metabolomics) were selected on the basis of already 
known magnoliid bioactive metabolites.  
In total 225 samples were analysed in both positive and negative ionisation modes 
(including blanks, PBQC, replicate samples). This represents 108 species with between 
1 and 3 biological replicates. 
 
3.3.3 UPLC-mass spectrometry analysis  
A Vanquish Flex™ liquid chromatography system comprising a vacuum degasser, 
binary pump, column oven and temperature controlled auto sampler was interfaced with 
a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Fisher 
Scientific). The LC parameters were as follows: LC column was a 2.1 × 100 mm, 1.8 
µm C18 Zorbax Eclipse plus (Agilent), column temperature was 30°C, and mobile 
phase flow rate was 0.6 mL/min with gradient elution. Mobile phase A was 0.1 % 
formic acid in water, mobile phase B was 0.1% formic acid in acetonitrile. The initial 
mobile phase composition was 5% B, which was increased linearly to 100% B over 8 




run time of 12 min. The MS was calibrated on the day of analysis. The MS data were 
obtained in both positive and negative ionization modes separately. The instrument 
settings were as follows: full scan range was 105-1500 m/z at a mass resolution 
240,000, the 255.23295 m/z ion was used as a lock mass in positive ionisation only, a 
maximum 8 MS/MS spectra per scan at 15,000 resolution were collected, precursor 
ions were selected on intensity order, the HCD normalised collision energy was 35% 
and dynamic exclusion for of 0.5 min was used. The AGC was set to 1x106 with a 
maximum injection time of 30 ms. The HESI ion source conditions were as follows: 
sheath gas flow rate 55 units, auxiliary gas flow rate 15 units, sweep gas flow rate 3 
units, spray voltage 4 kV positive, 4.2 kV negative, probe heater 450°C, capillary 
temperature 275°C, S- lens RF level 60.  The sample injection volume was 2 µL, blank 
and PBQC samples were run every 10 samples.  
 
3.3.4 Chromatographic deconvolution for GNPS analysis  
Both negative and positive ionization raw data were processed using the open source 
software MZmine 2 (mzmine.github) (Pluskal et al., 2010). The .raw files were 
converted to the .mzXML format and centroided using the open source software 
MSConvertGUI (proteowizard.sourceforge.net) to be compatible to MZmine 2 and 
GNPS down-stream processing. The converted files were then imported to MZmine 2 
software and mass detection was done for MS at 1 x 105 intensity threshold and MS/MS 
at 1 x 104 intensity thresholds. Chromatograms were built using ADAP chromatogram 
builder with a set threshold at 1 x 105 intensity, min height intensity at 5.0 x 104, m/z 
tolerance at 0.001. Chromatogram smoothing was done using wavelet chromatogram 
deconvolution at 1 x 105 min feature height and a peak duration range of 0.05-1.0 min. 
Chromatograms were deisotoped using isotopic peak grouper with mz tolerance at 
0.002 m/z and RT tolerance at 0.05 min. The chromatograms were then deconvoluted, 
deisotoped, and then aligned using RANSAC alignment with retention time correction 
of 0.08 min. The aligned peak list was gap filled using peak finder. Peaks were 
identified using the online MZmine 2, database search (using Kyoto Encyclopedia of 
Genes and Genomes /KEGG compound database and chemspider) option and also local 
custom data base search (Compound Discoverer 2.1, Thermo Fisher Scientific). The 




peak list MS attributes were exported to .csv format for descriptive statistical analysis. 
The MS/MS attributes were exported in .mgf format for Global Natural Product Social 
Molecular network (GNPS) molecular network analysis. Large data sets were processed 
using du.deakin.edu.au domain Deakin University server (Intel (R) Xeon (R) CPU E5 
2618L v3 @ 2.30GHz 2. 29GHz, 512 GB RAM 64 bit operating system- Analytix1 
server)  
 
3.3.5 Molecular networking  
The online workflow at Global Natural Product Social Molecular Network (GNPS) was 
used to generate molecular networks for both negative and positive ionization modes. 
The mass spectral alignment generated in .csv and .mgf formats using the MZmine 2 
software was used as input files for feature based molecular networking. Raw files were 
converted to .mzXML format using MSConvertGUI before uploading to GNPS 
spectrum files. Group mapping text files were generated for species, genus, family, 
order levels using MS Excel using the format on GNPS this file was uploaded under 
group mapping files. Analysis parameters were then adjusted as follows. Ms Cluster 
was run for a large data set, with maximum group size at 150. Parent mass tolerance 
was set at 0.2 Da and MS/MS fragment tolerance was set to 0.2 Da. Minimum group 
size was set for 2. Other parameter settings were kept at default values. For feature-
based molecular networking Ms Cluster was set off, and minimum group size was set 
to 1. The most informative molecular network was selected based on library 
identifications for previously known magnoliid metabolites (Appendix A-
Supplementary Material-Table 6.2). This was used for subsequent statistical analysis.  
 
3.3.6 Data analysis 
MZmine 2, peak alignments was used for partial least square discriminate analysis 
(PLS-DA) to visualise the separation of magnoliid families based on metabolomic 
profiles. This was done using the open source web server Metaboanalyst 
(www.metaboanalyst.ca) (Chong and Xia, 2018). Node information tables downloaded 




MS/MS spectra are shared between samples. Venn diagrams was generated using the 
limma R package (Ritchie et al., 2015).  PLS-DA was generated at family level and 
Venn diagram was generated at order level. Peak alignments were further used for 
hierarchical cluster analysis using the R package cluster (Maechler et al., 2018). The 
hierarchical cluster analysis was conducted using the Euclidean distance and Ward 
method.  
 
3.3.7 Metabolite identification with mass spectral libraries 
Thermo Fisher Scientific Compound Discoverer 2.0 (www.thermofisher.com) was used 
to obtain library identifications for the .raw mass spectral files MS scans. The 
identifications were based on ChemSpider and mzCloud libraries. The workflow used 
was as follows; input .raw files to Compound Discoverer 2.0 and form the workflow 
with the following nodes to obtain spectral identifications. The added nodes on the 
workflow are as follows; select spectra, align retention time, detect unknown 
compounds (mass tolerance; 5 ppm, min peak intensity; 5 E6), group unknown 
compounds, merge features (mass tolerance; 5 ppm, RT tolerance; 0.05 min), predict 
composition, search mzCloud, search mass lists (RT tolerance; 0.5 min, mass tolerance; 
5 ppm), fill gaps (mass tolerance; 5 ppm, S/N threshold; 1.5), normalize areas, mark 
background compound, search Chem Spider (KEGG; data base, mass tolerance; 5 ppm, 
max number of results; 100) and predict composition. The obtained identifications were 
















Figure 3.1: Summary workflow of sample collection, sample processing, mass spectrometry and data analysis using both mass spectrometry and 
mass spectrometry data processing software, and descriptive statistical analysis
 Stored at -80°C freeze dried  Young leaves harvested   
Sample extracted according to Foroughi et al., 2014 
UPLC- mass spectrometry analysis (Q Exactive™ HF Hybrid 
Quadrupole-Orbitrap™ Mass Spectrometer (Thermo Fisher Scientific)) 
.raw files processed using MSConvertGUI 
(proteowizard.sourceforge.net) (converted to .mzXML, centroid) 
.mzXML files processed using MZmine 2 (mass detection MS and 
MS/MS, ADAP chromatogram builder, wavelet chromatogram 
deconvolution, deisotoping, RANSAC alignment, gap filled and adduct 
filtered, peak identification (online libraries and custom data bases) 
GNPS Molecular networking (according to Allard et al., 2016, 
maximum group size=150, parent mass tolerance=0.2, MS/MS 
fragment tolerance=0.2, minimum group size=1 and using MS cluster) 
Peak list filtered for GNPS (MS/MS scan only)  
Descriptive statistical analysis Venn diagram (R3.4.1 limma package) 
 Peak list full scan (MS and MS/MS) 
 Descriptive statistical analysis  
 (Multivariate analysis (R3.4.1 ggbiplot 
package) 





Online library data bases 
(MZmine 2, related online search 
of KEGG, Massbank, and 
METLIN) 
 GNPS Molecular networking  Metabolite profile comparison 





3.4.1 Dataset validation and overall metabolomic profile analysis of magnoliids  
On average, approximately 1,800 molecular features per sample were detected, with a total of 
9843 unique molecular features (MS only) and 30762 MS/MS spectra representing a massive 
dataset for interrogation. The PBQC data showed excellent RT reproducibility with a 
coefficient of variation (CV) of 0.47%, mass variation of the caffeine internal standard was 
0.38 ppm, and peak area reproducibility CV was 9% (Appendix A- Supplementary Material- 
Table 6.3) validating the high quality of the dataset. PLS-DA analysis of the entire dataset for 
positive ionization showed separation of the samples of magnoliid families 
Atherospermataceae; Hernandiaceae; Lauraceae and Monimiaceae (Laurales), Myristicaceae 


















Figure 3.2: PLS-DA of the overall data set revealing separation of the magnoliid families based 
on the total metabolomic profile for positive ionization. Shaded area represents the 95% data 
confidence intervals for respective magnoliid families. Piperaceae (Piperales) = grey, 
Winteraceae (Canellales) = black, Myristicaceae (Magnoliales) = pink, Monimiaceae 
(Laurales) = aquamarine, Lauraceae (Laurales) = blue, Hernandiaceae (Laurales) = green, 






The positive ionization MZmine 2, full scan peak alignment cluster analysis revealed distinct 
clustering of related species, with species of the same genus showing the same branching 
patterns (Figure 3.3). This was also evident in the negative ionization MZmine 2, full scan peak 
alignment cluster analysis (Figure 3.4). Overall, these results show that taxonomically-related 
species are strongly similar in their total metabolic profiles within the magnoliid clade. In the 
hierarchical cluster analysis the family Lauraceae (of order Laurales) formed a major branch. 
However, the other families of the order Laurales (Atherospermataceae, Hernandiaceae and 
Monimiaceae) had chemical properties that placed them among the orders Piperales (family 
Piperaceae) and Canellales (family Winteraceae).  
The positive ionization data provided the greatest number of library identifications on MZmine 
2 (3 times more putative library identifications than the negative ionization data). Therefore 

























Figure 3.3: Hierarchical cluster analysis tree showing chemical similarities between Australasian 
magnoliids. Positive ionization data were used with Euclidean distance and Ward method. The species 
that are not in a box are species that showed no clear associations to major taxonomic clusters. The 
scale bar is the chemical dissimilarity.  
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Figure 3.4: Hierarchical cluster analysis tree using negative ionization data with Euclidean distance 
and Ward method. The scale bar is the chemical dissimilarity.  
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3.4.2 GNPS molecular networking and metabolite identification 
Figure 3.5 represents, using a Venn diagram, the division of parent ions between the magnoliid 
orders. The greatest proportion of unique parent ions (14,706 = 48%) were from the order 
Laurales, while 2887 (9.38%) of the parent ions were unique to the order Piperales. There is a 
sample bias for total parental ions in Laurales, because this is the most diverse magnoliid clade 
in Australasia, thus most of the sampled species belongs to this order. Furthermore only 5.44% 
of the parent ions were shared between all four magnoliid orders, however this still represented 
1673 parent ions in common. 
Analysis using GNPS yielded a large molecular network comprising 30762 parent ions with 
associated MS/MS spectra and close to 3656 network clusters (including small clusters of just 
two nodes). The nodes of the molecular network clusters were further divided into pie charts, 
which represent plant families of each species that produced the same parent ion. Thus if a 
network is displayed in a single colour, it signifies that the parent ion cluster is only expressed 





































Figure 3.5: Venn diagram showing unique and shared for parent ions (i.e. the number of parent 
ions shared between members of different orders) from the positive ionization GNPS molecular 
network. A total of 30762 parent ions were shared between four magnoliid orders (Canellales 
= red, Laurales = yellow, Magnoliales = blue and Piperales = green) with 339 parent ions in 
the blank samples 
 
3.4.3 Metabolites identified using standards compounds within the GNPS molecular 
network  
To validate this approach some known magnoliid specific standards were analysed during the 
UPLC-MS/MS analysis (Table 3.1). This resulted in the identification of piperine, a secondary 
metabolite specific to the order Piperales. Piperine (parent mass: 286.1438 m/z [M+H]+ ion) 
had six connecting nodes in the molecular network cluster (Figure 3.6). Adduct ions were 
removed during data processing, so these connecting nodes can be considered as structurally 
related compounds and potentially new bioactive  molecules. Including the node (parent mass: 
272.1281 m/z) bioactive metabolite; piperyline, which is an alkaloid described from Piper 
nigrum L. (black pepper). All other nodes with cosine scores more that 0.80 at all edges could 



























































Figure 3.6: GNPS molecular networking cluster with nodes and edges for piperine. The nodes 
are in pie charts to represent spectral division across the magnoliid orders. Shades of blue = 
Laurales, shades of green = Piperales. MS/MS spectra for each node parent ion are given with 
two library matches in circles. The corresponding taxa is given above each spectra. Each 
retention time for the parent ion is also indicated.  
 
The corresponding spectra were extracted from the raw mass spectral data to verify the MS/MS 















Library match piperine  




Table 3.1: Magnoliid specific bioactive metabolite standards and their reported bioactivity 
 
 
3.4.4 GNPS molecular networking and putative metabolite identified using open source 
libraries 
Except for piperine, the other standard compounds (limonene, quercetin and polygodial) were 
not identified through the GNPS molecular networking in the magnoliid samples. There are a 
number of potential reasons, for example, a compound may not reach the intensity threshold 
for chromatographic deconvolution, lack of spectral information for UPLC-MS in open 
libraries, or the metabolite  is simply absent in the analysed samples. Yet five more putative 
metabolite identifications were found using the GNPS online repositories (National Institute of 
Standards and Technology-NIST and Massbank) (Table 3.2). These compounds were 
identified previously as magnoliid specific with a distribution across species indicating a 













Piperaceae (Sunila and Kuttan, 
2004, Scott et al., 
2007, Gorgani et al., 
2017, Shang et al., 
2017) 
polygodial 234.33 antifungal and anti-
inflammatory 
Winteraceae (Loder, 1962, 
Charlwood, 1993), 
(Kubo et al., 2001) 
quercetin 302.24 antioxidant  Lauraceae 
predominantly 
(De Almeida et al., 
1998, Fang et al., 
2010) 
(Carvalho et al., 
2017) 
limonene 136.23 chemotherapic Lauraceae (Da Silva et al., 

















Phylogenetic distribution Reference 
coclaurine  benzylisoquinoline 
alkaloid  
found in magnoliid, Piperales 





found in many magnoliids, 






Mason et al., 
2016) 
isoquercetine flavanoid found in many magnoliid 
families  
(Wang et al., 
2012) 
kaempferol flavanoid found in many magnoliid 
families  




one or many analogues can be 
found in close to 75% of Piper 








one or many  analogues can be 
found in close to 75% of Piper 
species and is a specialised 






one or many analogues  can be 






The seven metabolites identified using GNPS open source library search were piperine, 
piperolanine, piperoleine, isocorydine, isoquercetine, kaempferol and coclaurine. Among 
these, piperine, piperolanine and piperoleine are compounds predominantly found in Piper 
species, and are insecticidal compounds (Scott et al., 2007). Isocorydine has been recently 
studied for anticancer activities and extracted from many species of magnoliids (Zhong et al., 
2014) (including family Atherospermataceae and Monimiaceae which is also evident in our 
results, Table 3.2). The plant families with records for the expression of above metabolites 
were in accordance with the already identified records of expression (Table 3.3). Of the above 
metabolites, the benzylisoquinoline alkaloid coclaurine has been previously as having an 
extensive evolutionary history in magnoliids, with diverse species shown to synthesise 
benzylisoquinoline alkaloids (Liscombe et al., 2005) (Figure 3.7). The resulting molecular 
network cluster indicates putative metabolites with similar structure to coclaurine from all the 












recorded for compound 
expression* 
Magnoliid families with 
potential analogue compounds 
from molecular network 
Potential medicinal taxa  
chlorogenic 
acid 
antioxidant  Lauraceae, Magnoliaceae 
and Winteraceae 
(Konczak et al., 2010, Lu 
et al., 2011) 







Hernandiaceae, Piperaceae and  
Winteraceae 
Atherosperma moschatum Labill., 
Daphnandra johnsonii Schodde, 
Daphnandra micrantha (Tul.) Benth. 
Hernandia bivalvis Benth.,        
Piper melchior (Sykes) M.A.Jaram. 
and Piper peltatum (L.) L'Hér. ex 
Aiton 
isocorydine anticancer, antitumor Annonaceae, 
Atherospermataceae, 
Lauraceae and 
Monimiaceae (Bick et 
al., 1956, Zhong et al., 
2014) 
same as already known same as already known 
isoquercetin antihistamine Annonaceae, Lauraceae, 
Piperaceae and 
Winteraceae  
Myristicaceae Myristica globosa subsp. muelleri 










recorded for compound 
expression* 
Magnoliid families with 
potential analogue compounds 
from molecular network 
Potential medicinal taxa  
kaempferol antioxidant Annonaceae and 
Lauraceae (De Almeida 
et al., 1998) 
Piperaceae and Winteraceae  Peperomia blanda (Jacq.) Kunth and 







Piperaceae (Sunila and 
Kuttan, 2004, 
Vijayakumar et al., 2004) 
Lauraceae and Winteraceae  Beilschmiedia collina B.Hyland, 
Beilschmiedia obtusifolia (F.Muell. 
ex Meisn.) F.Muell. and Tasmannia 
purpurascens (Vickery) A.C.Sm. 
pipernonaline 
piperolein b 
induce cell apoptosis  Piperaceae (De Souza 
Grinevicius et al., 2016) 
Lauraceae and Winteraceae Beilschmiedia collina B.Hyland, 
Beilschmiedia obtusifolia (F.Muell. 
ex Meisn.) F.Muell. and Tasmannia 
purpurascens (Vickery) A.C.Sm. 
Note* all the above plant family data were also verified against data from the KNApSAcK Metabolite Activity Database 









































Figure 3.7: GNPS molecular networking cluster with nodes and edges for 
benzylisoquinoline alkaloid, coclaurine. The nodes are in pie charts to represent spectral 
division across the magnoliid orders according to the given colour scale. The 
corresponding taxa is given above each spectra. Each retention time for the selected 
parent ion is also indicated  
 
The corresponding spectra were extracted from the raw mass spectral data to verify the 
MS/MS spectra against GNPS output for parent mass. (RT = retention time) 







The resulting GNPS node information was screened for already identified and described 
plant metabolites of pharmacological interest. This resulted in identification of a further 
eight putatively bioactive metabolites (with some that were not identified through 
MZmine 2 library search) and taxa expressing them (Table 3.3). The taxa were then 
screened at magnoliid family level against already existing literature for the expression 
of respective metabolites (this was done using the literature surveys and the 
KNApSAcK plant metabolite data base). This search identified 16 different instances 
of magnoliid families expressing bioactive metabolites, which had not previously been 
recorded in those families (Table 3.3). 
 
3.4.5 Molecular network clusters of unknown metabolites  
Of the 3656 network clusters in the GNPS output network, 5% had parent ions/nodes 
without library annotations. The 95% of the other network clusters were compounds of 
ubiquitous distribution across the magnoliid families, or compounds that were 
conserved for only particular magnoliid families or family combinations. Figure 3.8 is 
a representation of an unknown metabolite, which was only recorded from the genus 
Cryptocarya R. Br. (Lauraceae). This network comprises ten MS/MS nodes with their 































Figure 3.8: GNPS molecular network cluster with nodes and edges. The network 
corresponds to unidentified metabolites from species of genus Cryptocarya. MS/MS 
spectra for several node parent ion are given. The corresponding taxa is given above 
each spectra. Each retention time for the parent ion is also indicated  
The corresponding spectra were extracted from the raw mass spectral data to verify the 











3.5.1 Dataset validation and overall metabolomic profile analysis of magnoliids  
Identification of metabolites in untargeted mass spectrometry analysis from natural 
products is one of the major constraints in developing and identifying novel lead 
compounds, as absolute identification still relies on confirmation with standards (Xiao 
et al., 2012), (Sumner et al., 2007). I was able to use molecular networking to reveal 
molecular relationships that would be nearly impossible to discover manually. The high 
quality data produced here is an excellent example of the power of modern high 
resolution MS instrumentation and enabled new structurally related compounds to be 
discovered from known. To do this however a range of data processing tools were 
required for this complex dataset. Also, MZmine 2 (Pluskal et al., 2010), which is the 
second most used LC-MS data processing software required a high power computing 
facility for this large dataset, this may prove to be a limitation for the wider use of this 
approach on larger datasets (Weber et al., 2017). 
The descriptive statistical analysis of the full scan negative and positive ionization data 
sets, showed a similar clustering pattern of chemical similarities in related taxa (i.e. 
within the same magnoliid family). This highlights that related taxa contain similar 
chemical profiles, and the metabolomic profiles of magnoliids is a useful taxonomic 
tool. Chemosystematics, which is comparative phytochemistry applied to plant 
systematics, became a popular method for plant characterization during the early 1960s 
(Gibbs, 1963). It is re-emerging as a mode of understanding plant metabolomic 
diversity in the 21st century (Messina et al., 2014, Kang et al., 2019). For example, the 
sesquiterpene lactones and flavonoids have been identified as good markers in the 
molecular classification of the Asteraceae tribe Vernonieae (Gallon et al., 2018). In the 
present study, the total metabolome based hierarchical cluster analysis for magnoliids, 
which was obtained also follows the most recent magnoliid classification system (Chase 
et al., 2016). Yet there are notable incongruencies.  As an example, current magnoliid 
molecular phylogeny recognises two pairings of sibling orders: Piperales with 
Canellales, and Laurales with Magnoliales (Chase et al., 2016). The hierarchical cluster 
analysis for the total metabolomic profiles did not, however, place all the families of 
order Laurales together on the basis of chemical similarity, but rather showed a 




may be that secondary metabolites are more suited for distinguishing lower taxonomic 
levels (at genus level) rather than higher taxonomic levels (e.g. orders) (Wink, 1998). 
Furthermore, abiotic factors such as temperature, soil pH and salinity could also act in 
synergy with the biotic stressors which may affect the overall secondary metabolite 
profile of a plant, given the fact that synthesis of secondary metabolites is often a stress 
response (Telascrea et al., 2007, Murai et al., 2009, Sampaio et al., 2016). Hence under 
different environmental conditions all secondary metabolites may not be expressed 
similarly. Further such detailed chemical profiling could potentially allow description 
of environmental conditions impact on specialised metabolites. However, 
phytochemical data can complement classifications based on phylogenetic analysis of 
DNA data, biogeography, morphology and other evidence.  
Overall, the Partial Least Squares Discriminant Analysis (PLS-DA) highlighted little 
variation across the total metabolomic profiles of the taxa. This was expected as the 
taxa sampled belong to a single plant taxonomic clade (superorder: Magnolianae) and 
are replicated across different geographic areas. The lack of family level separation 
could be due to the close evolutionary and phylogenetic relationships between the 
sampled taxa and the tendency of closely related taxa to be similar is higher because of 
evolutionary constraints (Wink et al., 2018, Henz Ryen and Backlund, 2019), hence a 
complete separation of  families could not be observed in PLS-DA.  
Within the magnoliid clade I observed presence of metabolites that are explicit to 
certain families, as well as metabolites that were ubiquitous. This could be due to both 
shared metabolites and unique metabolites expressed across the magnoliids, reflecting 
different biological roles of different types of compounds. Recent research findings 
indicate that the secondary metabolite group flavonoids are more ubiquitous, whereas 
sesquiterpene lactones are more conserved, with the majority being produced across 
magnoliids with higher diversity among Canellales (Henz Ryen and Backlund, 2019).  
As an example although sesquiterpene lactones show a patchy distribution, the 
synthesis of these metabolites are attributed to a common evolutionary origin 
(Bohlmann et al., 1998). Hence the chemical diversity is driven by biotic or abiotic 
stressors, influencing the expression of certain genes and hence the presence of 
associated metabolites (Henz Ryen and Backlund, 2019). Canellales is the plant order 




orders (Massoni et al., 2015). Previous research indicated that the genus Pseudowintera 
Dandy of order Canellales produced drimane sesquiterpenoids (including polygodial) 
that are also expressed in liverworts and ferns (Asakawa et al., 2012). This early 
diverging evolutionary history could be a reason for members of the order Canellales 
to be diverse in sesquiterpenes whereas other orders, having had less time to develop 
defences, do not exhibit a large diversity of sesquiterpenes.  
Hierarchical cluster analysis has proven to be informative in guiding the 
chemotaxonomic studies of medicinal, food and aromatic plants (Hao and Xiao, 2015). 
In this study, hierarchical cluster analysis demonstrated clustering in species of the 
order Piperales. This could be related to the strong herbivore-plant interactions these 
taxa experience. The late Cretaceous diversification of the Piperales could have led to 
the expression of an array of secondary metabolites as defence mechanisms against the 
emerging herbivore diversity, and this diversity has a direct effect on the damage that 
the plants face (Richards et al., 2015). The Piperales are the most morphologically 
diverse magnoliid clade and also show a unique diversity for benzylisoquinoline 
alkaloids, which have been shown to increase overall plant fitness (Liu et al., 2014a, 
Mason et al., 2016).  
Benzylisoquinoline alkaloid secondary metabolites have been found in the orders 
Piperales, and Ranunculales, and also in the families Rutaceae, Lauraceae, Cornaceae 
and Nelumbonaceae (Liscombe et al., 2005). Studies into the occurrence of the enzyme; 
(S)-norcoclaurine synthase, responsible for benzylisoquinoline alkaloid synthesis, have 
revealed that this metabolic pathway originated only once (Liscombe et al., 2005). 
Hence the incongruence in the expression of these metabolites across all taxa of 
Lauraceae, could be due to mutations which may have inactivated the pathway genes 
or simply due to lack of detection. But it must be noted that plant ecophysiological 
needs also play a major role keeping these genes active or inactive (Liscombe et al., 
2005). This is supported by the putative identifications for the benzylisoquinoline 
alkaloid coclaurine in GNPS molecular networking.  
There are limitations in detecting the total metabolomic profile of species using a single 
experimental methodology in metabolomics. For instance, the extraction solvent and 
the Zorbax Eclipse Plus C18 column used in this research focus on extracting and 




alkaloids (Huie, 2002) (Xiao et al., 2012). In addition, the analysis mainly focuses on 
results obtained from positive ionization mode, which is more effective for flavonoids 
and alkaloids (Moco et al., 2006). The experimental methodology to some extent 
therefore determines which secondary metabolites are detected and therefore inherently 
limits the identification of the total secondary metabolite profile of a sample in such 
analyses. 
 
3.5.2 GNPS molecular networking and putative metabolite identification  
The 108 species of Australasian magnoliids sampled represent four orders: Canellales, 
Laurales, Magnoliales and Piperales. Out of the 108 species close to 25 species have 
scientific literature for their metabolites with medicinal or culinary importance 
(Brooker et al., 1987, Setzer et al., 2001, Buchanan et al., 2009, Earl et al., 2010, Lassak 
and Mccarthy, 2011, Hart et al., 2014, Winnett et al., 2014, Brophy et al., 2016).Yet 
many of the species studied here have not been chemically characterised, even though 
they are used medicinally. This research allowed us to show that closely related taxa 
are more chemically similar, which lead to the identification of target taxa for medicinal 
potential related to known useful compounds (Table 3.3).  
The GNPS molecular network analysis allowed the identification of major, magnoliid 
specific molecular network clusters. One significant network was the piperine specific 
molecular network cluster (Figure 3.6). In this particular network all the corresponding 
potential analogue nodes except one belong to the family Piperaceae. The one 
exception, the piperine analogue (parent ion: 246.112 m/z), was derived from the 
families Lauraceae and Winteraceae. This could be due to piperine metabolic pathways 
being highly phylogenetically conserved across the magnoliid lineage (French et al., 
2018). 
Piperine is responsible for the medicinal and pungent properties of the family 
Piperaceae. The biosynthesis of piperine alkaloids is dependent on piperoyl-CoA and 
piperidine, which is a Piper amide precursor (Geisler and Gross, 1990, Huan et al., 
2015). The expression of this specific pathway has only previously been described from 
Piperaceae. Within Piperaceae there are records of other similar biosynthetic pathways 




L. and Peperomia Ruiz and Pav. producing similar secondary metabolites, yet there are 
no in depth studies on what has caused this potential convergence (Kato and Furlan, 
2007). The genes responsible for the synthesis of the terpene biosynthetic pathway 
enzyme; 3-hydroxy-3-methylglutaryl coenzyme A reductase were derived from a single 
ancestor gene. The expression of this enzyme is phylogenetically conserved and related 
taxa exhibit the same 3-hydroxy-3-methylglutaryl coenzyme A reductase genes across 
the plant kingdom (Kato and Furlan, 2007). Thus there could be a similar scenario 
governing the expression of piperine alkaloids in Piperaceae, which differentiates 
piperine expression in the magnoliid clade. Similarly, I was able to identify potential 
analogue compounds for coclaurine, isoquercetine, kaempferol and linoleic acid, from 
magnoliid families previously not accounted for expressing these metabolites.   
There are also molecular network clusters that are ubiquitous across plant families and 
orders. Recent research conducted on marine seaweeds has also been able to 
characterise species specific molecular network clusters as well as molecular network 
clusters that are ubiquitous (Kessler and Baldwin, 2002, Philippus et al., 2018). This 
could also be the effect of the evolutionary history these taxa share. Secondary 
metabolites are predominantly induced responses to herbivore stress. Therefore they 
have the potential to be upregulated or downregulated depending on the extent of 
herbivore stress and damage caused to the plant (Pandey et al., 2017). In the molecular 
network cluster related to the benzylisoquinoline alkaloid; coclaurine, all the magnoliid 
families in this study share the molecular network cluster, highlighting that there are 
potential compounds with similar structure to coclaurine amongst the group. Earlier 
research highlighted that benzylisoquinoline alkaloids are found across the Lauraceae 
and members of the order Piperales (Custódio and Veiga Junior, 2014), signifying an 
underlying genetic basis for the biosynthetic pathway across related magnoliid taxa.  
There are limitations of what this approach could provide. For instance much of the 
focus has been on already known medicinal metabolites, available in spectral libraries. 
There are number of network clusters in a given molecular network, which lack 
metabolite identification, which may be of potential medicinal importance (e.g. the 
molecular network cluster for Cryptocarya R.Br. in Figure 3.8). Also the sample biases 
and lack of replicates may also affect the overall results and the detectability of certain 




represents the existing diversity of magnoliids in Australasia. The findings and the 
potential medicinal taxa I have identified could be further studied, to structurally 
characterise the metabolites. Further bioactivity analysis could also help in dissecting 
true medicinal potential of the identified analogue compounds.  
Chemical analysis showed clustering patterns of some of the closely related taxa 
(families) according to chemical similarity. The GNPS molecular networking identified 
seven potentially medicinal secondary metabolites and potential target taxa for the 
expression of those bioactive metabolites. Among these, the presence of piperine was 
confirmed with standards compounds and the resulting molecular network cluster 
allowed us to identify potential analogue compounds, both from taxa of Piperales as 
well as the families Lauraceae and Winteraceae. These compounds could be further 
verified through isolation and chemical characterisation. The chemical complexity and 
lack of comprehensive plant chemical databases is still a key challenge for natural 
product discovery workflows. The approach used here however has enabled the 
identification of occurrence of potential medicinal compounds from the thousands that 
were detected based on the similarity of the MS/MS spectra. The taxa identified through 
GNPS molecular networking can now be studied further, as novel sources of 
metabolites of medicinal importance. 
 
3.6 Supplementary material 
1. Appendix A- Supplementary Material- Figures 6.1 
2. Appendix A- Supplementary Material- Table 6.1 
3. Appendix A- Supplementary Material- Table 6.2 







4. CHAPTER THREE 
Phylogenetic signal analysis of secondary metabolomic 
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4.1 Abstract  
Plants produce a myriad of bioactive specialised metabolites. Some of these specialised 
metabolites enhance plant fitness and hence their expression is under natural selection. 
One consequence of this is that the expression of particular metabolites is evolutionarily 
conserved and associated with certain lineages. Thus there is a tendency for closely-
related plant taxa to produce similar metabolites. Many of these metabolites are used 
for medicinal purposes, so examining the phylogenetic signal of bioactive specialised 
metabolites can form the basis for examining whether related taxa could be used for 
similar medicinal purposes. However, so far this approach has focussed on the 
expression of single compounds rather than the complex blends in which they typically 
occur. Furthermore, it has rarely been studied in depth using novel advancements in 
metabolomics. In this study I use mass spectrometry, molecular networking and 
phylogenetics to identify evolutionary patterns of specialised metabolism in 69 taxa 
from the Australasian magnoliids, a group comprising species from the orders 
Piperales, Canellales, Magnoliales and Laurales. The magnoliids clade has an 
established high incidence of traditional medicinal use worldwide. The results show a 
significant phylogenetic signal for the traditional medicinal use of sampled species. 
Closely-related species share overall similar chemical composition and further analysis 
provided weak, but significant, phylogenetic signal for 11 compounds of known 
medicinal importance in the magnoliid clade; camphor, chlorogenic acid, cryptowoline, 




and rutin. Further molecular networking identified other taxa within the magnoliid 
clade likely to express structurally similar bioactive metabolites in the molecular 
network clusters corresponding to piperine and coclaurine. Thus this approach is 
effective in predicting phylogenetic patterns of metabolomic traits as well as identifying 
medicinal potential of related taxa. These taxa could be relevant candidates for future 
investigations to establish their medicinal potential. 
Keywords: magnoliid, medicinal plants, molecular networking, phylogenetic signal, 





















More than 200,000 specialised plant metabolites have been identified providing an 
evolutionary advantage by enabling sessile plants to adapt to their environment 
(Pichersky and Lewinsohn, 2011). They have roles beyond growth, development and 
reproduction, acting for example as defensive compounds induced by herbivory and 
pathogen attack, chemical cues for pollination and seed dispersal, or allelopathic 
compounds affecting other plants (Pichersky and Gang, 2000). These specialised 
metabolites can be broadly categorized as either alkaloids, fatty acid metabolites, 
phenolics, polyketides and terpenoids and often these compounds are biologically 
active (bioactive compounds are defined as compounds that can have an effect on 
human health) (Biesalski et al., 2009, Ekanayaka et al., 2015). Their bioactive 
properties result from interactions between the compounds’ chemical functional groups 
and cellular targets, mediating a diversity of cellular reactions (Wink, 2015). The 
bioactive properties of these specialised plant metabolites have also been exploited by 
humans for thousands of years as medicines to treat infections and health disorders 
(Gurib-Fakim, 2006).   
These compounds confer fitness and survival benefits to plants, so the genes responsible 
for specialised metabolites exhibit high plasticity and are under strong natural selection 
(Wink, 2003, Hartmann, 2007). External stressors such as herbivores or environmental 
factors can upregulate, downregulate or silence the expression of these genes in 
secondary biosynthesis pathways.  For example, in cruciferous plants, differential gene 
expression has been shaped by natural selection for elevated synthesis of glucosinolates 
that deter pests. This has been same for many other volatiles and essential oils in plants. 
In this case, tissue damage by herbivores causes hydrolysis of glucosinolates, 
generating bioactive compounds that act as defence chemicals (Benderoth et al., 2006, 
Figueiredo et al., 2008). In response, insects can develop counter-adaptations such as 
detoxification, synthesis of antioxidants, canal trenching and chewing (Després et al., 
2007). Further adaptations of herbivores and pathogenic microorganisms to overcome 
plant host defences (reciprocal adaptations to overcome plant specialised metabolite 
toxicity), have also exerted an evolutionary constraint on plant secondary metabolism 




metabolites has been shaped by underlying genetics as well as external selective 
pressures, resulting in evolutionary patterns across plant lineages (Wink, 2003).   
The medicinal potential of a plant is related to the specialised metabolite profile that it 
expresses. Therefore an understanding of the expression of these specialised bioactive 
metabolites, in the light of evolutionary relationships provides the potential for 
medicinal properties of plant clades more broadly to be identified (Rønsted et al., 2012, 
Yessoufou et al., 2015, Ernst et al., 2016). Several studies indicate that the expression 
of some of these specialised metabolites are lineage-specific due to underlying 
evolutionary constraints (Rønsted et al., 2008, Zhu et al., 2011, Rønsted et al., 2012). 
Hence some plant lineages are significantly more likely to possess bioactive compounds 
as sources of human therapeutics. Consequently, phylogenetic patterns in plant groups 
that human populations have chosen for their bioactive properties can be observed 
(Roersch, 2010, Saslis-Lagoudakis et al., 2011a). This phylogenetic pattern implies that 
the specialised metabolite synthetic pathways are also conserved across plant lineages 
(Chae et al., 2014). If this is the case there should be a pattern of evolutionary related 
taxa being chemically more similar and thus exhibit similar bioactive properties.  
Shared patterns in the specialised metabolite profiles across plant lineages can be 
studied using conventional chemotaxonomic approaches (Reynolds, 2007) combined 
with molecular phylogenetic analysis. However, another informed approach for 
identifying potential medicinal taxa works by identifying metabolomic markers (such 
as specialised metabolites that are associated with certain plant lineages) (Liu et al., 
2017, Souza et al., 2018). The first step of this approach involves using chemical 
screening of plant taxa to build metabolomic similarity profiles. This can be achieved 
by hyphenated chromatography mass spectrometry techniques. For plant specialised 
metabolites, Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) is 
widely used to generate metabolomic profiles which can then be compared across plant 
taxa (Hostettmann et al., 2001, Wolfender et al., 2003).  
These metabolomic approaches could be used to improve the prediction of medicinal 
potential. Out of the estimated 200,000 plant specialised metabolites present in plants 
only a small portion have been chemically identified or their medicinal potential well 
studied (Rai et al., 2017, Alseekh and Fernie, 2018). Novel techniques like mass 




that are structurally similar to already known bioactive metabolites (Allard et al., 2016). 
In molecular networking the fragmentation pattern of a molecule using collision 
induced dissociation (MS/MS) is compared across metabolite profiles. Molecules with 
similar fragmentation patterns are then scored based on their chemical relatedness due 
to similar key structural components. These are then grouped into network clusters, 
where a single cluster refers to a single group of metabolites that likely share many 
similar chemical (and hence bioactive) properties. Therefore this technique allows one 
to identify groups of potentially bioactive metabolites by comparison to compounds 
with known bioactivity.  
An analysis of the phylogenetic signal (a quantitative measure of the tendency of 
closely-related species to be phenotypically similar in contrast to species drawn at 
random from the same phylogeny (Blomberg et al., 2003)) can improve the likelihood 
of identifying a new bioactive metabolites. Phylogenetic signal can be used to 
determine if metabolites, or metabolite network clusters, exhibit phylogenetically 
conserved expression, or are randomly distributed across the phylogeny. Phylogenetic 
signal can be measured via a number of metrics for data that are continuous 
(quantitative) or discrete (e.g. presence/absence) (Münkemüller et al., 2012, Kamilar 
and Cooper, 2013). In a medicinal value context, Fritz and Purvis’s (2010) D statistic 
(Fritz and Purvis, 2010) has been used in several studies to compare the phylogenetic 
distribution of presence/absence of both medicinal use and expression of particular 
compounds across plant species and whether this conforms to either a random 
distribution or distribution that would be expected if the trait had evolved by Brownian 
motion (gradual divergent evolution) (Saslis-Lagoudakis et al., 2015). This metric has 
for example been used to identify trait signals in the family Amaryllidaceae  in relation 
to alkaloid diversity (Rønsted et al., 2012), in Artemisia L. to identify antimalarial 
properties (Pellicer et al., 2018), in Aloe L. Burm.f. to measure patterns in leaf habit 
and succulence (Grace et al., 2015) and in Euphorbia L. to determine the phylogenetic 
signal in plant use and toxic diterpenoids (Ernst et al., 2016, Ernst et al., 2018).  
The ancient angiosperm lineage of magnoliids is one of 11 plant clades previously 
identified with high levels of bioactivity and medicinal potential (Zhu et al., 2011). This 
group contains close to 10,000 species belonging to four plant orders that originated 




magnoliid clade comprises most of the species which are considered as basal 
angiosperms. It includes the orders Magnoliales and Laurales (sister clades), and 
Piperales and Canellales (sister clades). Relationships between taxa in magnoliids have 
been comprehensively studied using molecular phylogenies which required up to five 
genes (Zanis et al., 2002, Soltis and Soltis, 2004, Massoni et al., 2014). The recently 
published Angiosperm Phylogeny Group (APG) IV classification (Chase et al., 2016) 
accounts for 18 magnoliid families following Massoni et al.’s (2014) classification of 
the magnoliid clade.   Due to the unique evolutionary history of Australasia, magnoliids 
harbour a reasonable level of diversity (c. 350 species) and endemism in the region 
(Hunter, 2003). Close to 10% of taxa in the Australasian magnoliid clade have 
documented traditional medicinal uses or culinary uses, which also supports the 
previously identified significantly high in vitro bioactive properties of the clade (Coley 
et al., 2003). Species from Atherospermataceae, Monimiaceae, Lauraceae, 
Winteraceae, Eupomataceae and Piperaceae have been identified to contain many 
medicinal utilities. As such they make a good clade for further study of chemical 
profiles and medicinal potential. 
The objective of this study was to integrate LC-MS/MS metabolomic screening, 
molecular networking and phylogenetic signal analysis to identify the evolutionary 
patterns of plant specialised metabolite expression in a clade of angiosperms that has 
been previously identified as having a high degree of medicinally relevant bioactivity. 
As in the previous studies, the hypothesis is that that species will both exhibit significant 
phylogenetic signal of metabolite expression and tend to be chemically similar. This 
property in turn may help to identify clades or taxa of medicinal relevance. 
 
4.3 Materials and Methods 
4.3.1 Identification of pre-documented bioactive metabolites and medicinal taxa 
A literature survey was conducted to identify documented medicinal use of magnoliid 
taxa in Australasia. Magnoliid taxa (native/naturalised taxa) for the region were 
identified using the Atlas of Living Australia (http://www.ala.org.au), Flora of 
Australia (Wilson, 2007) and Flora of New Zealand (Breitwieser et al., 2010). 




“Māori medicinal plants”, “medicinal Canellales”, “medicinal Laurales”, “medicinal 
Magnoliales” and “medicinal Piperales” were also used through an EBSCOhost search. 
In part, the information obtained from these searches informed our taxon sampling (see 
below).  
 
4.3.2 Taxon sampling 
Magnoliid leaf samples were harvested for 69 taxa, during the southern summers of 
2015, 2016 and 2017 across Australian and New Zealand arboreta as detailed in 
Appendix A- Supplementary Material (Table 6.1). The 69 taxa were selected to best 
represent the diversity of magnoliid genera (4 out of 5 Atherospermataceae genera, all 
Eupomataceae genera, 1 out of 2 Hernandiaceae genera, 3 out of 7 Monimiaceae genera, 
7 out of 8 Lauraceae genera, 1 out of 2 Piperaceae genera, 1 out of 2 Winteraceae 
genera), from the 108 taxa used for chemical analysis in Chapter Two. Samples from 
taxa were also replicated across different geographical locations when possible. The 
species included representative of all four magnoliid orders (Canellales, Piperales, 
Laurales and Magnoliales). Two young leaves were harvested for each taxa. Fresh 
leaves were stored in zipper seal bags with label tags and were transferred to laboratory 
under frozen conditions in insulated containers. They were stored at -80°C as freeze 
dried samples until metabolomic analysis. Another sample of leaves were silica dried 
and stored with excess silica in zipper seal bags until DNA extractions. 
 
4.3.3 Chemical analysis  
4.3.3.1 Sample preparation 
The samples stored at -80°C were subsequently frozen in liquid nitrogen and 
homogenized to a fine powder. The homogenized leaf powder was kept frozen at -80°C. 
50 mg of the homogenized leaf powder was used for metabolomic extractions. The leaf 
powder was placed in Eppendorf  tubes with 1/4 volume of homogenising silica beads 
(Sigma-Aldrich), followed by the addition of 300µl of the extraction solution 




HPLC grade (Foroughi et al., 2014). Samples were then placed in a cooled Retsch mill 
and extracted at 30 Hz for 2 min. Following extraction, tubes were centrifuged at 14,000 
rpm and supernatant transferred to 2 ml HPLC vials. A pooled biological quality control 
sample (PBQC) was also prepared by combining 5 µl aliquots of each extract. Extracts 
were stored at -80°C until further analysis. Solutions containing 10 µM of the following 
compounds of analytical grade; caffeine, piperine, quercetin, polygodial and limonene 
were also prepared and analysed. The latter four compounds are known bioactive 
metabolites in magnoliids (Table 4.1).  
 
Table 4.1: Magnoliid-specific bioactive metabolite standards and their bioactivity 
 
4.3.3.2 Ultra-Performance Liquid Chromatography (UPLC)-mass 
spectrometry analysis  
I carried out UPLC-mass spectrometry using a Vanquish Flex™ liquid chromatography 
system comprising a vacuum degasser, binary pump, column oven and temperature 
controlled autosampler. This was interfaced with a Q Exactive™ HF Hybrid 













(Sunila and Kuttan, 
2004, Scott et al., 2007, 
Gorgani et al., 2017, 
Shang et al., 2017) 
polygodial 234.33 Winteraceae antiinflammatory 
and antimicrobial 
(Loder, 1962, 
Charlwood, 1993, Kubo 
et al., 2001) 
quercetin 302.24 Lauraceae 
predominantly 
antioxidant (De Almeida et al., 
1998, Fang et al., 2010, 
Carvalho et al., 2017) 
limonene 136.23 Lauraceae antimicrobial (Miller et al., 2013, Da 




was a 2.1 × 100 mm, 1.8 µm C18 Zorbax Eclipse Plus (Agilent). The column 
temperature was 30°C, and mobile phase flow rate was 0.6 mL/min with gradient 
elution. Mobile phase A, was 0.1 % formic acid in water, mobile phase B was 0.1% 
formic acid in acetonitrile. The initial mobile phase composition was 5% B, which was 
increased linearly to 100% B over 8 minutes with a 2 minute hold at 100% B then re-
equilibration for 2 minutes at 5% B. Altogether total run time of 12 minutes. The mass 
spectrometer was calibrated on the day of analysis. The MS data were obtained in both 
positive and negative ionization modes separately. The full scan range was 105-1500 
m/z at a mass resolution 240,000. A maximum of 8 MS/MS spectra per scan at 15,000 
resolution were collected, with precursor ions selected on intensity order. The high 
energy collision dissociation (HCD) normalised collision energy was 35%. The 
automatic gain control (AGC) was set to 1 x 106 with a maximum injection time of 30 
ms. The Heated electrospray ionization (HESI) ion source conditions were as follows: 
sheath gas flow rate 55 units, auxiliary gas flow rate 15 units, sweep gas flow rate 3 
units, spray voltage 4 kV positive, 4.2 kV negative, probe heater 450°C, capillary 
temperature 275°C, S- lens RF level 60.  The sample injection volume was set to 2 µl, 
with blank and pooled biological quality control (PBQC) samples run at every 10 
samples.  
 
4.3.3.3 Molecular networking  
The online workflow at Global Natural Product Social Molecular Network (GNPS) was 
used for molecular networking. Raw mass spectral files were converted to .mzXML 
format using MSConvertGUI before uploading to GNPS spectrum files. Group 
mapping text files were generated for species, genus, family, order levels using MS 
Excel using the format on GNPS and this file was uploaded under group mapping files. 
Ms Cluster was run for a large data set, with maximum group size at 150. Parent mass 
tolerance was set at 0.2 Da and MS/MS fragment tolerance was set to 0.2 Da. Minimum 
group size was set for 2. Other parameter settings were kept at default values. The 
resulting molecular network was examined for library identifications and the output 





4.3.4 Phylogenetic analysis  
DNA from 20 mg of silica dried leaf samples was extracted using a Qiagen DNeasy 
plant mini kit (Qiagen, Copenhagen, Denmark). Amplifications were done for the 
plastid rbcL and plastid matK genes for sequencing following standard protocols. The 
rbcL gene was amplified using primers RH-1S (sequence: 5’-ATG TCA CCA CAA 
ACA GAA ACT-3’;(Petersen and Seberg, 2003) and rbcL ajf634R (sequence: 5’-GAA 
ACG GTC TCT CCA ACG CAT-3’;(Fazekas et al., 2008). The matK gene was 
amplified using matK-fx (sequence: 5’-TAA TTT ACG ATC AAT TCA TTC-3’; (Ford 
et al., 2009) and matK-5R (sequence: 5’-GTT CTA GCA CAA GAA AGT CG-3’; Ford 
et al., 2009) primers.  
The rbcL and matK strands were sequenced at Macrogen (Copenhagen, Denmark). 
Both strands were sequenced for each region for all taxa. Sequences were edited and 
assembled using the software Geneious v.9.1.8 (Biomatters Ltd, Auckland, New 
Zealand, (Kearse et al., 2012). All sequences will be submitted to Genbank during the 
review process. Sequences were aligned using default MUSCLE (Edgar, 2004) 
alignment as implemented in Geneious. 
The matK gene was selected because in this study all the taxa are evolutionarily closely-
related and span across 20 genera and the matK gene has been previously shown to be 
informative in contrast to other regions in resolving species and family level 
evolutionary relationships (Johnson and Soltis, 1994). This is largely due to its 800-900 
base pair (bp) ideal size, high substitution rate with low transition and transversion ratio 
and mutationally conserved sectors. Thus this acts as a good discriminatory marker for 
the phylogenetic hypothesis while the rbcL provides a rigorous back bone owing to the 
fact that it is easy to amplify and align for majority of angiosperms (Hollingsworth et 
al., 2011).  
Phylogenetic estimation was conducted using Bayesian inference. All characters were 
included in the analysis and gaps were treated as missing data. Bayesian analysis of the 
combined dataset was performed with MrBayes v3.2.6 (Ronquist and Huelsenbeck, 
2003). The best fitting model was selected using jmodeltest-2.1.10 (GTR + I + G; 
Parameters: lset NST = 6 RATES = gamma) of molecular evolution using the Akaike 




were unrooted. The analysis was performed with 1,000,000 generations on 4 Monte 
Carlo Markov chains. The run was completed at average standard deviation <0.01 after 
820,000 generations and the burn-in was determined using the software Tracer v1.7.1 
(burnin; 107700, effective sample size: 632; (Rambaut et al., 2018). A 50%-majority 
rule consensus tree was created using the software PAUP 4.0a (Swofford, 2003).  In 
instances where the phylogenetic relationships could not be resolved using the two 
barcoding genes only, the branch polytomies were arbitrarily resolved and given a 
minimal length of 1 x 10-7. 
 
4.3.5 Comparison of overall chemical similarity with phylogeny 
To determine whether closely-related species were overall more chemically similar, a 
Mantel test was used according to Rønsted et al., (2012). For the Mantel test the 
phylogenetic distance pairwise matrix was constructed based on ultrametric 
phylogenetic distances (summed branch lengths) between species, and the overall 
chemical similarity (for total metabolite profiles of MZmine 2 Aligned filtered peak list 
MS attributes file) matrix was constructed as the binary squared Euclidean distance 
which counts up the total number of differences in presence/absence of traits between 
species (Symonds et al., 2009). These distances were calculated in the R package ape 
(Paradis and Schliep, 2018). The Mantel test was performed using GenAlEx 6.5 
(Peakall and Smouse, 2012).  To visualise the phylogeny in bivariate chemical space a 
phylomorphospace PCA was done. The phylogenetic tree previously obtained was 
projected on to the chemical space, on PCA axes generated using R package, ggplot 2 
(Wickham, 2016.). This was done using the function phylomorphospace on R package, 
phytools (Revell, 2012).  
 
4.3.6 Phylogenetic signal analysis for putative bioactive metabolites 
The correlation of chemical profiles with phylogeny was analysed using the D metric 
developed to measure the phylogenetic signal of binary traits (Fritz and Purvis, 2010). 
Individual metabolites or metabolite clusters (see below) were scored as characters 




the R packages caper (Orme et al., 2018) on R 3.5.1 (2018).  The value of D is calculated 





where Sobs = observed number of state changes in the binary trait along the phylogeny; 
Sb = mean number of state changes generated from 1000 simulations of the evolution 
for the character by a Brownian motion model of evolution with likelihood of change 
being specified as that which produces the same number of tip species with each 
character state as the observed; and Sr = mean number of changes generated from 1000 
random permutations of the species values at the tips of the phylogeny.  
An observed D value = 1 indicates that there is no phylogenetic signal in the trait in 
question and the distribution of the trait across species is equivalent to that given by a 
random distribution (Sobs=Sr). By contrast, a phylogenetically highly correlated trait has 
D = 0, indicating that the trait is distributed in the manner predicted by a Brownian 
motion model of gradual evolution of the trait (Sobs=Sb). P values for the D metric were 
generated using 1000 permutations of both random and Brownian motion models of 
trait distribution, to measure the significance of the deviation of D from 1 (non-
phylogenetic/random distribution) or from 0 (phylogenetically highly correlated 
distribution).  
Bioactive metabolites for phylogenetic signal analysis were selected on the basis of 
previously collected information during the literature survey on magnoliid-specific 
metabolites. These metabolites were screened from the MZmine 2 aligned filtered peak 
list; MS attributes file. Further magnoliid specific putative bioactive metabolite 
molecular network clusters, were selected for phylogenetic signal analysis. This was 
done using the molecular network clusters that had library identifications, which 








4.4.1 Phylogenetic hypothesis in comparison with published magnoliid 
phylogeny  
The topology of the resulting phylogeny (Figure 4.1) was in congruence with previously 
published phylogenies for magnoliids (Zanis et al., 2002, Massoni et al., 2015, Soltis 
and Kliebenstein, 2015, Chase et al., 2016).  
 
Figure 4.1: Phylogenetic hypothesis for super order Magnolianae orders Canellales, 
Laurales, Magnoliales and Piperales. The phylogenetic tress was obtained with 
Bayesian inference for 1,000,000 replicates (Colour coding according to taxonomic 
family- black = Atherospermataceae, green = Piperaceae, red = Trithuria submersa 
(basal angiosperm), turquoise = Eupomataceae, pink = Winteraceae, yellow = 





4.4.2 Relationship between overall chemical similarity and phylogeny 
The Mantel test showed a significant correlation between chemical difference and 
phylogenetic distance, indicating that closely related taxa tend to have a more similar 
chemical profile. This was true for both negative (Mantel Test; r=0.329, P=0.001) and 
positive (Mantel Test; r=0.680, P=0.001) ionization data, yet the correlation, especially 
with the negative ionization data, while significant, was not strong (Figure 4.2). The 
level of chemical similarity between related taxa was also evident from the 
phylomorphospace PCA analysis. The nodes corresponding to related taxa were 
clustered together in the phylomorphospace, where the phylogeny was projected onto 























































Figure 4.2: Plot of Mantel test showing the relationships between; A) chemical distance 
and phylogenetic distance for the negative ionization data and, B) chemical distance 
and phylogenetic distance for the positive ionization data for 69 species in the 









































































































Figure 4.3: Phylomorphospace of PCA values on overall chemical similarity of taxa 
based on metabolomic profile data. PC1 accounts for 23% of the variance and PC2 
accounts for 16% of the variance. The colours correspond to all nodes descending from 
the common ancestor of each family.  Colour coding is in accordance with magnoliid 
family: grey = Atherospermataceae, green = Piperaceae, pink = Winteraceae, yellow = 

























4.4.3 Phylogenetic distribution of medicinal properties in magnoliids 
Known medicinal use was mapped on to the phylogeny (Figure 4.4) and the 
relationships between medicinal use and phylogeny was assessed using the D metric. 
Out of the 69 taxa in the phylogenetic hypothesis, 13 were already identified as having 
medicinal uses (Table 4.2). These 13 taxa belonged to families Atherospermataceae, 
Lauraceae, Monimiaceae, Eupomataceae, Piperaceae and Winteraceae. Phylogenetic 
signal analysis gave a weak but significant, phylogenetic signal for documented 
traditional medicinal uses (D=0.449; Probability of D = 1, resulting from random 
distribution of the trait across the phylogeny, P = 0.003; probability of D = 0 resulting 
from Brownian phylogenetic structure/ gradual divergent evolution P = 0.040). 
Medicinal taxa are phylogenetically conserved across the magnoliid phylogeny in the 
current study and they are predominantly distributed among Atherospermataceae and 

































Figure 4.4: Phylogenetic distribution of previously known traditional medicinal 






Table 4.2: Known medicinal taxa amongst Australasian magnoliids 
Order Family  Species Common name Medicinal uses/ 
properties 
Reference 
Laurales Atherospermataceae Atherosperma 
moschatum Labill. 
Black sassafras diuretic and laxative (Lassak and 
Mccarthy, 2011) 





(Brophy et al., 2016) 
Laurales Atherospermataceae Doryphora 
aromatica 
(F.M.Bailey) L.S.Sm. 
Grey sassafras  antimalarial  (Buchanan et al., 
2009) 
Laurales Atherospermataceae Doryphora sassafras 
Endl. 
Golden sassafras  antimalarial (Buchanan et al., 
2009) 
Laurales Atherospermataceae Laurelia novae- 
zelandiae  A.Cunn. 
Pukatea  antibacterial,  eczema 
and toothache  
(Brooker et al., 1987, 
Earl et al., 2010) 
Laurales Monimiaceae Hedycarya 
angustifolia  A.Cunn. 
Australian mulberry  stings and cut 
wounds 




Laurales Monimiaceae Hedycarya arborea  
J.R.Forst. & G.Forst. 
Pigeonwood medicinal vapour 
baths 
(Brooker et al., 1987, 
Brophy et al., 2016) 
Laurales Lauraceae  Litsea calicaris 
(A.Cunn.) Benth. et 
Hook.f. ex Kirk 
Mangeao. Tangeao. medicinal vapour 
baths 
(Bennett, 1883,) 
Canellales  Winteraceae Tasmannia 
lanceolata (Poir.) 
A.C.Sm. 
Mountain pepper  antimicrobial,  
digestive relief and 
venereal diseases  
(Winnett et al., 2014) 
Canellales Winteraceae Tasmannia stipitata  
(Vickery) A.C.Sm. 
Dorrigo pepper analgesic, diarrhoea, 
inflammation and 
ulcers 
(Hart et al., 2014) 
Magnoliales  Eupomataceae Eupomatia laurina  
R.Br. 
Bolwarra  antibacterial, 
diarrhoea and 
dysentery 
(Khan et al., 2003, 
Bryant and Cock, 
2017) 
Piperales  Piperaceae Piper auritum  
Kunth. 




(Martínez et al., 
1996) 










4.4.4 Phylogenetic signal of magnoliid bioactive metabolites  
I identified a total of 18 putative bioactive metabolites from the MZmine 2 metabolomic 
data processing both at mass spectral negative and positive ionization mode (Table 4.3). 
These are compounds that have previously been described and identified in magnoliids. 
The presence of piperine was verified by using standard compounds during the UPLC-
MS/MS analysis.  The rest of the 17 metabolites were putative annotations that were 
based upon MZmine 2 currently available online library searches (Masbank, METLIN, 
ChemSpider). These 18 metabolites formed the basis of the analysis of phylogenetic 
signal in medicinal compounds. 
 
Table 4.3: Bioactive metabolites previously characterised from magnoliid families that 





magnoliid family:  
Reference  
camphor Lauraceae (Liu et al., 2016, Zhou and Yan, 
2016) 
chlorogenic acid Lauraceae and 
Magnoliaceae 
(Fang et al., 2010, Lu et al., 2011) 
cinnamomumolide Lauraceae (Yu et al., 2012) 
cryptocaryolone Lauraceae (Smith and O Doherty, 2003) 
cryptowoline Lauraceae (Ewing et al., 1953) 
daphnin Atherospermataceae (Bick et al., 1960)  
daphnoline Atherospermataceae (Bick et al., 1960) 
hernandaline Hernandiaceae (Cava et al., 1966) 
hernandine Hernandiaceae (Cava et al., 1966) 
isocorydine Atherospermataceae, 
Annonaceae, 
Lauraceae and  
Monimiaceae 








magnoliid family:  
Reference  
kaempferol Lauraceae  (De Almeida et al., 1998) 
lauroscholtzine Lauraceae  (Glasby, 1975) 






myristoleic acid Lauraceae and 
Myristicaceae 
(Iguchi et al., 2001) 
piperine Piperaceae (Sunila and Kuttan, 2004, Scott et 
al., 2007, Shang et al., 2017)  
polygodial Winteraceae (Loder, 1962, Charlwood, 1993) 
rutin Magnoliaceae (Fang et al., 2010) 
 
 
From the 18 medicinal metabolites examined I found a significant phylogenetic signal 
for 11 metabolites; camphor, chlorogenic acid, cryptowoline, daphnin, kaempferol, 
lauroscholtzine, limonene, myristoleic acid, piperine, polygodial and rutin (Table 4.4; 
Figure 4.5). Some compounds had significant but weak phylogenetic signal, the 
observed D value was significantly different from both random distribution of the trait 
(D = 1) and distribution of the trait as expected under a Brownian motion model (D = 
0). However, camphor, chlorogenic acid, rutin, cryptowoline, lauroscholtzine and 
myristoleic acid exhibited a strong signal that was statistically indistinguishable from 





















camphor -6.205* 0 0.904 
chlorogenic acid 0.251* 0.012 0.299 
cinnamomumolide 0.953 0.350 0 
cryptocaryolone 0.200 0.056 0.503 
cryptowoline -5.609* 0 0.897 
daphnin 0.744* 0.029 0 
daphnoline 0.677 0.074 0.067 
hernandaline 1.170 0.671 0.006 
hernandine 1.009 0.485 0 
isocorydine 0.943 0.293 0 
kaempferol 0.531* 0 0.002 
lauroscholtzine -6.865* 0 0.921 
limonene 0.828* 0.017 0.008 
myristicin 1.018 0.556 0 
myristoleic acid -0.180* 0 0.691 
piperine 0.457* 0 0.014 
polygodial 0.774* 0.043 0 
rutin 0.453* 0.003 0.094 
P >0.05 indicates that the observed value is not significantly different from the 
given D values.* = values that are significantly different from D = 1, indicating 

























Figure 4.5:  Circular heat map for distribution of specialised metabolites with significant phylogenetic signal across 69 magnoliid species. The 


























4.4.5 Phylogenetic signal of potential bioactive metabolite analogues identified 
using GNPS molecular networking  
I also measured the phylogenetic signal for the analogues of previously known 
magnoliid bioactive metabolites, putatively identified in the GNPS molecular network 
clusters (Table 4.5). These included networks associated with compounds previously 
identified through MZmine 2 library search (piperine and isocorydine; given in Table 
4.2) and two metabolites putatively identified (coclaurine and isoquercetine) through 
GNPS structural similarity search.   Here, a single molecular network cluster was 
considered as a ‘character’ representing the presence or absence of a putative medicinal 
metabolite. 
 
Table 4.5: Phylogenetic signal in bioactive specialised metabolites and related 







D P (D=1)/Random 
or No Phylogenetic 
signal 




piperine 0.293* 0.001 0.271 
coclaurine 0.733* 0.033 0.001 
isocorydine 0.887 0.182 0 
isoquercetine 0.890 0.171 0 
P >0.05 indicates that the observed value is not significantly different from the 
given D values.* significant values 
 
I found weak but significant phylogenetic signal for the coclaurine network, and a 
stronger signal for the piperine network that conformed to a gradual Brownian motion 
model. For the other two compound networks there was no significant phylogenetic 
signal, with the observed values being not statistically different from that expected from 




piperine allowed us to identify three taxa from Piperaceae for the expression of the 
metabolites. The piperine corresponding network cluster also identified one taxon from 
the Lauraceae and one taxon from Winteraceae previously not known to express 
piperine analogue compounds (Figure 4.6). In Figure 4.6, two species are already 
known medicinal taxa. Hence the other three taxa are potential medicinal taxa, 
expressing piperine analogue compounds. The benzylisoquinoline alkaloid; coclaurine 
has previously been recorded from genera in Atherospermataceae, Lauraceae and 
Monimiaceae in the magnoliid group. The coclaurine corresponding molecular network 
cluster indicate the presence of metabolites structurally similar to coclaurine, also from 
Hernandiaceae and Piperaceae. Further I also observed molecular network clusters 
where a metabolite was expressed across multiple magnoliid families, yet the 

























Figure 4.6: Heat map for taxa expressing A) piperine and B) coclaurine identified using 
GNPS molecular network clusters C) and D) respectively. 
 Potential medicinal taxa expressing piperine and coclaurine identified based on the 
molecular network clusters  










4.5.1 Phylogenetic distribution of medicinal magnoliids 
Previous investigations into ethnobotanic knowledge on medicinal plants have 
identified phylogenetically ‘hot’ clades with medicinal properties, with several families 
being predominantly used for treatment of related health conditions across different 
cultures (Saslis-Lagoudakis et al., 2011b). This could be either due to phylogenetic 
congruence in actual medicinal potential (i.e. shared chemical similarities) (Saslis-
Lagoudakis et al., 2012), or in how apparent the taxa are to humans (Saslis-Lagoudakis 
et al., 2015). Combining chemical analysis with molecular phylogenetic based 
approaches provides the capacity to investigate these possibilities, and predict 
medicinal potential in other plant taxa that is so far less documented in the scientific 
literature. 
In this study, I examined the phylogenetic distribution of medicinal magnoliids in 
Australasia. Known medicinal use showed significant phylogenetic signal. This is also 
in accordance with the recent research findings in relation to medicinal species of 
Euphorbiaceae, medicinal species of genus Aloe L. and for medicinal species of genus 
Artemisia L. (Grace et al., 2015, Ernst et al., 2016, Pellicer et al., 2018).  In the current 
study, medicinal use was concentrated within Atherospermataceae, Monimiaceae, 
Eupomataceae, Piperaceae and Winteraceae families, but not the family Lauraceae. 
Lauraceae is one of the most diverse magnoliid families in Australasia. Yet the recorded 
utilities of laurels are predominantly for timber or for culinary use as spices (Bootle, 
2010).  In terms of specialised metabolite profiles, tree species that are used for timber 
are generally more diverse for terpenoids and phenolics (Celedon and Bohlmann, 
2018).  Research conducted to distinguish edible, medicinal and timber yielding plant 
taxa based on total metabolomic content, does not provide clear differentiation between 
edible/medicinal plants and timber yielding plants (Liu et al., 2017). According to our 
results there were piperine analogous metabolites present in Lauraceae, which may 
potentially be bioactive. Therefore, although there is no recorded used of Lauraceae 
species for medicinal purposes except for in Litsea calicaris (A.Cunn.) Benth. et 
Hook.f. ex Kirk from New Zealand, the taxa could also potentially harbour medicinally 
relevant specialised metabolites not recognised in traditional medicine or not recorded 




4.5.2 Relationship between overall chemical similarity and phylogeny 
Mantel tests have been used previously to show the correlation between phylogenetic 
distance and chemical diversity in plants (Thomas et al., 2009, Rønsted et al., 2012, 
Salazar et al., 2018). The results here indicated that closely related species were indeed 
more chemically similar. This is also reflected in some metabolites showing a strong 
phylogenetic signal in relation to the magnoliid phylogeny (see below). Previous 
studies into the correlation between chemical similarity and phylogeny of 
Amaryllidaceae has also identified statistically significant correlations between 
phylogeny and chemistry (Rønsted et al., 2012).  
The chemical similarities of closely-related species may be due to underlying genetics 
and conserved specialised metabolite synthetic pathways. Research on diverse 
organisms from algae to angiosperms has shown lineage specific expansion and 
clustering of genes related to specialised metabolite synthetic pathways (Chae et al., 
2014).  Furthermore the taxonomic distribution of plant specialised  metabolites, shows 
evidence of gradual divergent evolution of these compounds in plants since they moved 
to land from water (Weng and Chapple, 2010). This was evident from the taxonomic 
distributions of specialised metabolomic pathways that correlated with major branching 
points in the plant kingdom. For example phenylpropanoids and flavonoids are absent 
in extant charophytic algae but ubiquitous in land plants, and the evolution of trichome 
related defence compounds coincides with the origin of the angiosperms, gymnosperms 
and ferns  (Weng, 2014). 
  
4.5.3 Phylogenetic signal of magnoliid bioactive metabolites  
We found significant phylogenetic signal for 11 bioactive metabolites. This is in 
accordance with previous records of weak, but significant phylogenetic signal in 
alkaloid secondary metabolite profiles of Amaryllidaceae as well as volatile terpene 
secondary metabolite profiles of closely related angiosperm taxa (Rønsted et al., 2012, 
Courtois et al., 2016). Further significant phylogenetic signal has been documented in 




The 11 magnoliid metabolites with significant phylogenetic signal were camphor, 
chlorogenic acid, cryptowoline, daphnin, kaempferol, lauroscholtzine, limonene, 
myristoleic acid, piperine, polygodial and rutin. Thus the significant phylogenetic 
signal could indeed be a result of the monophyletic expression of the underlying genes 
behind these compound synthesis. The biosynthetic pathway information for the above 
metabolites is given in Table 4.6. Except for piperine biosynthesis and the expression 
being conserved to Piperales (Bunsupa et al., 2012), there are no in-depth analyses on 




Table 4.6: Information on biosynthetic pathways for the identified specialised metabolites 
 
Specialised metabolite  Biosynthetic pathways Plant groups reported References  
camphor terpenoid biosynthetic pathways Laurels  (Chen et al., 2018) 
chlorogenic acid derived from precursors of schikimate 
biosynthetic pathway  
ubiquitous across plant kingdom  (Venkataramaiah et al., 2007) 
cryptowoline dibenzopyrrocoline alkaloids biosynthetic 
pathway  
Cryptocarya laevigata Blume 
(Lauraceae) 
(Ewing et al., 1953) 
daphnin derivative of phenylpropanoid 
biosynthetic pathway 
not described from magnoliids  (Satô and Hasegawa, 1969) 
kaempferol flavonol biosynthetic pathway ubiquitous across plant kingdom (Patschke and Grisebach, 1968) 
limonene monoterpene biosynthetic pathway Canellales, Laurales, Magnoliales, 
Piperales,  
(Sharkey et al., 2013, Da Silva 
et al., 2017) 
lauroscholtzine isoquinoline alkaloids biosynthetic 
pathway  
Lauraceae and Monimiaceae  (Zhang et al., 2014, Fuentes-
Barros et al., 2018) 
myristoleic acid  biosynthesised from myristic acid Myristicaceae  (Kwon et al., 2015) 
piperine piperine biosynthetic pathway Piper nigrum L. pathway is expected 
to be present across Piperaceae  




Specialised metabolite  Biosynthetic pathways Plant groups reported References  
polygodial sesquiterpenoid biosynthesised from 
drimenol  
Winteraceae  (Henquet et al., 2017) 
rutin combination of phenyl proponoid and 
flavonol biosynthetic pathways  





Among the compounds polygodial has been identified in several magnoliids, including 
genera from Canellaceae and Winteraceae (order Canellales). This is a major compound 
extracted from Pseudowintera colorata (Raoul) Dandy (horopito) in New Zealand, 
which has been widely used for medicinal preparations due to its antibacterial and 
antifungal  properties (Nadia et al., 2018). Polygodial is a sesquiterpene, and several 
species of Pseudowintera Dandy have species specific polygodial derivative 
sesquiterpenes (Wayman et al., 2010). However, the genes related to the polygodial 
biosynthetic pathway have not been elucidated and the evolutionary history of the 
pathway is not known in this genus (Wayman et al., 2010). Recent studies in the order 
Caryophyllales have elucidated the enzymes and genes for polygodial synthesis, which 
include pathway specific enzymatic reactions and genes (Henquet et al., 2017). Hence 
further understanding of the biosynthesis-related genes could validate whether the 
phylogenetic signal is indeed due to conserved gene expression.  
The expression of piperine shows a significant phylogenetic signal for the magnoliids 
and is specific to the family Piperaceae (Bunsupa et al., 2012). Species of the genus 
Piper L. have been widely reported to produce piperine, which has antifungal properties 
(Sharma et al., 2016). This compound is also responsible for the pungent flavour of 
Piper species. Recent comparative studies on the biosynthetic pathways of Piperales 
genera Piper and Peperomia have revealed biosynthetic lineages with shared 
similarities between the two genera. As an example the orsellinic acid-based chromenes 
in Peperomia and Piper were structurally similar yet originate from two different 
biosynthetic pathways (Massuo and Furlan, 2007). Hence while the compounds may be 
taxonomic markers, they are derived convergently and the selective pressures that 
govern these similarities are  not understood (Massuo and Furlan, 2007). Even within a 
family there is a large variation in relation to the specialised metabolite biosynthetic 
pathways, but there is significant evidence of related species within a genus to exhibit 
the same metabolites derived from those biosynthetic pathways.  
The flavonol kaempferol and the terpenoid limonene are ubiquitous in the plant 
kingdom (Miean and Mohamed, 2001). These aromatic compounds are found in many 
edible plants and provide antioxidant, anti-inflammatory and anticancer properties 




broad abundance of medicinal and aromatic spices among the sampled magnoliids, 
could be the reason for the observation of these metabolites across the study species.   
More generally, the distribution patterns of specialised metabolites across lineages have 
often been used as a taxonomic markers, given the lineage specificity of certain 
metabolites (Martins and Nunez, 2015). For example, analysis of specialised 
metabolites across Fabaceae, Lamiaceae and Solanaceae revealed that some 
metabolites were specific to all subfamilies. Within the Lamiaceae, two closely related 
subfamilies expressed similar iridoid metabolites, but many iridoids showed a scattered 
distribution across related subfamilies (Wink, 2003). It has been stated that expression 
of specialised metabolites could be an adaptive trait regulated by genes with high 
plasticity (Hartmann, 2007, Wink, 2013). Although the ancestral genes are present 
within a particular clade, they could be mediated to turn on or off, hence it would result 
in either scattered or random distributions of specialised metabolites across related taxa  
(Wink, 2003). Further the apparently random distribution patterns of certain specialised 
metabolites across plant lineages could be a result of convergent evolution. For 
example, recent studies into the benzoxazinoid biosynthesis in monocots and dicots 
have highlighted that the production of certain specialised metabolites across several 
unrelated lineages could be due to convergent evolution of homologous genes (Frey et 
al., 2009, Dick et al., 2012). Convergent evolution in plant specialised metabolism has 
also been considered to be more common across lineages than expected, due to the fact 
that some metabolites (e.g. linalool) are very common across the whole plant kingdom 
(Pichersky and Lewinsohn, 2011). Therefore some metabolites are likely to be 
dispersed across multiple lineages, while some are lineage-specific (i.e. polygodial, 
piperine) and some are ubiquitous (i.e.; kaempferol, limonene).  
The possibility to predict the occurrence of specialised metabolites is limited by the 
lack of knowledge about the distribution and regulation of biosynthetic pathways and 
the influence of environmental factors. Furthermore by increasing the number of 
samples per taxa and making the phylogeny more exhaustive a better estimate of the 
phylogenetic signal of these specialised metabolites could be provided. Additionally, 
an understanding of the environmental and ecological predictors of specialised 
metabolite expression is needed to better elucidate the expression of metabolites across 





4.5.4 Phylogenetic signal of potential bioactive metabolites analogues identified 
using GNPS molecular networking  
GNPS molecular networking is currently referred to as a next generation drug discovery 
strategy (Quinn et al., 2017). It has been successfully used to identify novel bioactive 
metabolites from microbes as well as plant taxa (Nothias et al., 2018).  This approach 
was used in the current research to identify potential bioactive metabolites and taxa 
exhibiting those metabolites. Ultimately such an approach may lead to the identification 
of target magnoliid taxa for further investigation for medicinal activity. The results 
indicated significant phylogenetic signal for the molecular network clusters 
corresponding to the specialised metabolites coclaurine and piperine.  
Coclaurine is regarded as the universal precursor for benzylisoquinoline alkaloid 
biosynthesis in plants. Benzylisoquinoline alkaloids have been found in Magnoliales, 
Laurales, Piperales, Canellales and Ranunculales, and also in Rutaceae, Cornaceae and 
Nelumbonaceae (Liscombe et al., 2005). The enzyme (S)-norcoclaurine synthase, a key 
part of the metabolic pathway responsible for benzylisoquinoline alkaloid synthesis, 
has a single evolutionary origin (Liscombe et al., 2005). Hence the incongruence in the 
expression of these metabolites could be due to mutations in metabolic pathway genes 
which may have inactivated the genes. By contrast, plant ecophysiological needs (i.e. 
soil salinity, water content, herbivores) would have further kept these genes active in 
several plant clades (Liscombe et al., 2005). This is in line with the observation of 
putative identifications for benzylisoquinoline alkaloids in the MZmine 2 library 
database search and in the GNPS molecular networking. All the magnoliid families 
expressed potentially structurally related compounds to coclaurine in the molecular 
network. This families included species from genera, Atherosperma Labill., 
Beilschmiedia Nees, Cinnamomum Schaeff., Cryptocarya R.br., Daphnandra Benth., 
Doryphora Endl., Endiandra R.Br., Eupomatia Orb., Hedycarya J.R.Forst. & G.Forst., 
Hernandia L, Laurelia Juss., Laurus L., Litsea Lam., Neolitsea  (Benth. & Hook.f.) 
Merr., Piper L., and Wilkiea F. Muell. . These genera hence could be further studied for 




The molecular network for piperine, is more phylogenetically constrained and 
comprises of Piper excelsum (Forst.f.), Piper hederaceum (Miq.) C.DC., Piper 
melchior (Sykes) M.A.Jaram. and Piper novae-hollandiae Miq. - species that originated 
in the southern Pacific region. Our results identified potential piperine analogous 
metabolites present in Lauraceae (Beilschmiedia obtusifolia F. Muell. ex Meissner.) 
and Winteraceae (Tasmannia purpurescens (Vickery) A.C.Sm.). Piper species from 
Asia and South Pacific are of monophyletic origin (Jaramillo and Manos, 2001) and 
share the piperine amides amongst the old world species (Dyer et al., 2004). The 
number of taxa expressing piperine and piperine analogous are fewer in our GNPS 
output, in contrast to the MZmine 2 based heat map (given in Figure 4.5). This could 
be due to different thresholds set at data analysis using GNPS. These piperine amides 
are deterrents for herbivores. Piperine amides have the ability to effect the 
chemosensory receptors of insects and mammals acting as  plant defence compounds 
(Startek et al., 2019). Recent research of the phytochemical diversity of the Piper 
species from Costa Rica has identified that with increased phytochemical diversity the 
insect damage to plants progressively declines (Richards et al., 2015). Hence there 
could potentially be evolutionary constraints driven by herbivore pressure that 
determine expression of piperine amides.  
However one limitation of the analysis is the effect that may arise due to lack of 
biological replicates for some species. Given that expression of secondary metabolites 
could be induced/ suppressed by environmental conditions there could be the risk of 
different stressors in different locations determining the presence of some of the 
detected secondary metabolites. This research assumed that this problem was mitigated 
as arboreta collections should under minimal stress due to controlled pest free 
environments and managed abiotic stressors. Further, production of these secondary 
metabolites through upregulation or a downregulation is costly. Consequently plants 
should minimize this metabolomic cost through downregulating the production of these 
metabolites in absence of herbivores and external stressors. Therefore the study could 
be primarily investigating constitutive metabolites, under minimal stress conditions 
(Mithöfer and Boland, 2012). Specific understanding of induced metabolite production 
could be obtained through sampling two populations of the same species for 




In the current research, our approach was to link the novel metabolomic identification 
process of GNPS molecular networking to phylogeny, in an attempt to understand the 
evolutionary constraints on medicinal plant distribution across a clade. I have identified 
phylogenetic signal for 11 metabolites; camphor, chlorogenic acid, cryptowoline, 
daphnin, kaempferol, lauroscholtzine, limonene, myristoleic acid, piperine, polygodial 
and rutin. I have also identified potential other taxa within the magnoliid clade, which 
may express structurally similar medicinal metabolites in the molecular network 
clusters corresponding to piperine and coclaurine. This is a novel approach that could 
identify new medicinal taxa based on the assumption that evolution plays a major role 
in shaping plant specialised metabolite diversity. This research also highlights the 
usability of this approach in annotating potential new compounds from magnoliids as 
there were several clusters which could not be annotated using already available 
metabolomic information.  
Subsequently this information could potentially be used for a statistical predictive 
approach to identify medicinal species. This could be achieved by further studying 
phylogenetic predictive statistics and applying it across phylogenies with known 
metabolomic profiles (Guénard et al., 2013, Guénard et al., 2017). Hence, it could 
provide a research approach to predict medicinal potential of an uninvestigated taxon 
based on the combination of phylogenetic placement and metabolomic profiles. This 
could further streamline the plant-based bioactive natural product discovery process, 
and emphasises how human use of medicinal plants reflects deep and long-term 
knowledge of their bioactive function.  
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5. CHAPTER FOUR 
Predicting medicinal potential in plants using 
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5.1 Abstract  
Identifying new plants with medicinal potential from the vast diversity of plants has 
always been challenging. Conventionally in the pharmaceutical industry this was based 
on traditional knowledge, or using random sampling. Traditional medicine has been 
highly successful, but is limited in identifying new leads by being based on local plants 
for local uses. A random approach is inefficient, because there are more than 300,000 
known plants in the world, and simple random screening is therefore highly time 
consuming. During the past decade more systematic approaches, based on 
metabolomics, have been utilised by natural product chemists to investigate plants with 
medicinal potential. Yet, metabolomic information is not easily obtainable for many 
species due to reasons such as accessibility to plant material, and limitations in 
characterising the diverse metabolome using a single analytical method. In such cases, 
phylogenetic predictive approaches could potentially become a useful technique for 
predicting unknown metabolomic profiles. This is because closely-related species tend 
to have similar chemical properties due to shared evolutionary processes. In this study 
we used the metabolomic profiles and a phylogenetic framework of 69 Australasian 
magnoliid species to obtain and test the predictions for the medicinal potential using 
Phylogenetic Eigenvector Mapping. Results indicated over 60% of the predictions 
made were consistent with observed metabolomic data. The predictions based on 
Phylogenetic Eigenvector Mapping were also fairly robust to the degree of phylogenetic 




of the medicinal potential of a target taxon within a known phylogenetic framework. 
Therefore even in the absence of metabolomic data, phylogenetic prediction statistics 
could be used to identify target taxa for further metabolomic investigation.  
Keywords: lead discovery, medicinal plants, Phylogenetic Eigenvector Mapping, 
























Biological traits are more likely to be similar in organisms sharing a common 
evolutionary ancestry (Hansen and Martins, 1996). These phenotypic traits could be at 
the whole-organism scale (morphology, physiology, behaviour), or at the metabolomic 
or molecular scale. Therefore expression of such traits across species may be related to 
their phylogeny (Revell et al., 2008). The expression of certain traits may also be 
evolutionarily constrained. As an example the upstream regulatory enzymes of certain 
secondary metabolite pathways in plants are under strong selective constraints, hence 
evolving more slowly (Caseys et al., 2015). In such cases changes in gene expression 
are less likely to happen in closely-related species meaning that they would be more 
likely to share the same trait. These traits could have evolved through adaptation to 
either an abiotic factor such as a shared environment or a biotic stressor such as 
herbivory on a plant. This relationship between the trait and the phylogeny can be 
quantified through phylogenetic signal analysis. 
Phylogenetic signal can be defined as the statistical phylogenetic non-independence of 
a trait due to shared evolutionary history (Revell et al., 2008) or the extent to which 
closely-related species resemble each other (Blomberg and Garland, 2002). There are a 
number of metrics for measuring phylogenetic signal in traits that are either continuous 
(quantitative) or discrete (e.g. presence/absence/binary data) (Fritz and Purvis, 2010, 
Münkemüller et al., 2012, Kamilar and Cooper, 2013). These metrics are widely used 
to understand the correlation of traits in ecology and comparative analyses 
(Münkemüller et al., 2012). Some of the widely used phylogenetic signal indices for 
continuous traits include Pagel’s λ, Blomberg et al.’s K, Moran’s I and Abouheif’s C 
mean, and Fritz and Purvis’ D metric for binary, discrete traits (Moran, 1950, Abouheif, 
1999, Pagel, 1999, Blomberg et al., 2003, Fritz and Purvis, 2010).  
Phylogenetic signal analysis has been widely used in recent years to understand plant 
medicinal properties and how these are predicted by phylogeny. Here, specific 
metabolites are treated as a trait and related plant taxa are expected to share similar 
metabolites (Rønsted et al., 2008, Saslis-Lagoudakis et al., 2011a, Rønsted et al., 2012, 
Saslis-Lagoudakis et al., 2012, Saslis-Lagoudakis et al., 2015). One widely discussed 
implication of this pattern is that the identification of potential medicinal plants through 




Given significant phylogenetic signal in such metabolites, previously unstudied plant 
species that are closely related to species with known bioactive compounds would also 
be expected to express those, or similar, compounds. However, while many of the above 
studies have discussed the potential of phylogeny to predict metabolite expression, few 
have actually attempted to derive novel predictions of chemical traits, or potential 
medicinal properties. 
A way to resolve this problem is to predict the value of the trait using statistical 
probability based on trait correlations with related taxa with known trait profiles. This 
so-called “Hidden State Prediction” approach (Zaneveld and Thurber, 2014) can be 
achieved using Phylogenetic Eigenfunctions (PE), with the two recently defined 
approaches Phylogenetic Eigenvector Regression (PVR) and Phylogenetic Eigenvector 
Maps (PEM) (Guénard et al., 2013, Diniz-Filho et al., 2015). Of these two approaches 
PEM takes in to account an evolutionary model and  have a better predictive ability 
when there is a strong phylogenetic signal in traits, as PVR is a data-driven generalised 
model (Diniz-Filho et al., 2015). Therefore PEM could prove to be an informative 
approach to predict metabolomic traits when there is a phylogenetic signal.  
Predicting the unknown trait values from phylogenies requires estimating the 
underlying trait evolution process (Guénard et al., 2013). PEM does this based on graph 
theory which provides robust estimates of character/trait states. PEM can calculate a 
trait value of a variable depending on phylogenetic relationships (Fleischle et al., 2018). 
To construct a PEM of a trait, a set of taxa with known traits (model taxa) and a set of 
taxa without trait data (target taxa) are required. If the model taxa and target taxa have 
a known phylogeny, then it is possible to apply the PEM model and statistically predict 

















Figure 5.1: Basic theory behind phylogenetic eigenvector mapping (PEM) based on the graph theory; A) Phylogeny with tips and nodes referred 
to as vertices where pairwise relationship between vertices are calculated (i.e. X, Y, Z). Each branch is denoted as an edge (i.e. E1 to E4) which 
can be used to define the influence of vertices (species) on each other; B) An influence matrix is generated that defines the ‘inheritance of trait’ 
i.e. the extent to which the ancestral branches influence the expression in the descendants (the species); C) Edge weighing is done according to 
the given formulae, with weighted matrices leading to the predictions using PEM 
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Matrix is a graphical 
structure for the 
phylogeny A 
Binary matrix 
All species in the phylogeny 
A), are placed within this 
matrix (both model and target 
species). 
Influence matrix  
Edge weighing–
dynamic of trait 
change along the edge 





a- steepness parameter 
𝜑𝜑- evolution rate of the 
trait  



































model species  
A) Vertices 
(tips and ancestors) 
To calculate target species 
values, the relative position 
of the target species is 
substituted by an estimate 





This eigenvector approach thus models the evolution of a trait from ancestor to 
descendant. Using the comparative matrices (Figure 5.1) the model of evolution of the 
given trait can be imputed and then used to predict the target taxa trait value with 
statistical confidence. During the last five years this PEM approach has been emerging 
as a mode to predict these traits of target taxa when obtaining the trait value is difficult 
due to extinctions, or impracticality/expense associated in collecting trait data (Guénard 
et al., 2015).  
Here we use PEM to predict the medicinal potential of plant taxa using their 
metabolomic profiles as the predictor trait. The predictive power of PEM is expected to 
be higher when the given trait shows significant phylogenetic signal. Hence 
metabolomic features (i.e. bioactive specialised metabolites produced by a plant group 
that are medicinally useful to treat human infections and diseases), that have previously 
been identified as having significant phylogenetic signal (as a result of gradual 
divergent evolution), provide an excellent opportunity to test the predictive power of 
phylogeny in determining the presence of bioactivity. PEM has been previously applied 
for continuous trait prediction, yet given that eigenvector functions could be applied to 
both variation in discrete and categorical variables, here we apply them to presence/ 
absence traits (Diniz-Filho et al., 2012).  
The target plant group for this study was the Australasian magnoliids, a basal 
angiosperm clade that originated 125 million years ago (Massoni et al., 2015). 
Magnoliids comprise c.350 species in Australia and New Zealand. Close to 10% of taxa 
in the Australasian magnoliid clade have documented traditional medicinal uses or 
culinary uses, consistent with previously identified significantly high bioactive 
properties of the clade (Coley et al., 2003, Zhu et al., 2011). These medicinal taxa 
include well-known traditional medicines in Aboriginal bush medicine, and Māori 
medicinal systems such as Tasmannia lanceolata (Poir.) A.C.Sm. (mountain pepper) 
and Piper excelsum G.Forst. (kawakawa) (Taylor, 1870, Winnett et al., 2014). The 
magnoliid clade produce a myriad of medicinal metabolites including camphor, 
cinnamomumolide, daphnin, piperine and polygodial (Bick et al., 1960, Loder, 1962, 
Sunila and Kuttan, 2004, Yu et al., 2012, Liu et al., 2016, Zhou and Yan, 2016, Shang 
et al., 2017). These metabolites are responsible for both the medicinal and culinary 




The aim of this study was to use the bioactive metabolites expressed by medicinal 
magnoliids that showed significant and non-significant phylogenetic signal to predict 
the medicinal potential of a target taxon (for which the phylogenetic position is known 
and metabolomic profile is ‘missing’). We then compare our prediction with the actual 
metabolomic profile to assess the accuracy of prediction. We therefore assess the 
capacity for PEM-based prediction to determine metabolomic profiles and thereby its 
capacity to predict potential medicinal value across a phylogeny when no data for 
specific taxa are available.  
 
5.3 Materials and Methods 
5.3.1 Metabolomic and DNA analysis 
Metabolomic profile analysis and DNA analysis was carried out as described in detail 
in Chapter two and Chapter three. The same data generated in Chapter two and three 
were used here for subsequent PEM analysis. 
Briefly, magnoliid leaf samples were harvested for 69 taxa during the summers of 2015, 
2016 and 2017 across Australian and New Zealand arboreta. Two young leaves were 
silica dried for DNA extractions, and another sample of two leaves were stored at -80°C 
for subsequent chemical analysis. 
Homogenized leaf samples were extracted for total specialised metabolomic profile 
following (Foroughi et al., 2014). To obtain metabolomic mass spectral data, I carried 
out UPLC-mass spectrometry using a Vanquish Flex™ liquid chromatography system 
comprising a vacuum degasser, binary pump, column oven and temperature controlled 
auto sampler, interfaced with a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ Mass 
Spectrometer (Thermo Fisher Scientific). Metabolomic data were collected for both 
positive and negative ionization mode. These spectral data were analysed using open 
source software MZmine 2 (Pluskal et al., 2010).  
The complete methodology for estimation of the phylogeny of the magnoliid species 
was described in detail in Chapter three. Briefly, DNA from silica dried leaf samples 




Amplifications were done for the plastid rbcL and plastid matK genes for sequencing 
(Petersen and Seberg, 2003, Fazekas et al., 2008, Ford et al., 2009). Sequences were 
edited and assembled using software Geneious (Biomatters Ltd, Auckland, New 
Zealand) (Kearse et al., 2012). Phylogenetic estimation was conducted using Bayesian 
inference. Bayesian analysis of the combined dataset was performed with MrBayes 
v3.2.6 (Ronquist and Huelsenbeck, 2003) to obtain the resulting phylogeny.   
 
5.3.2 Statistical analysis  
5.3.2.1 Phylogenetic signal of the metabolites 
The relationship of chemical profiles to phylogeny was analysed using the D metric 
developed to measure the phylogenetic signal of binary traits (Fritz and Purvis, 2010). 
Individual biological active metabolites unique to the magnoliid clade were identified 
from previously published literature (see Results for details). The metabolomic data 
were investigated for library identifications of these compounds. Then those 
metabolites were scored for each species using binary coding as absent (0) or present 
(1). The value of D was calculated using the R package caper (Orme et al., 2018) on R 
3.5.1 (2018), where D = 1 indicates a trait with no phylogenetic signal (i.e. equivalent 
to being randomly distributed among species in the phylogeny) and D = 0 indicates 
strong phylogenetic signal (equivalent to the distribution of the trait across species that 
would be predicted from a gradual Brownian motion model of evolution). 
 
5.3.2.2 PEM to predict metabolite expression in target taxa  
To make a phylogenetically informed prediction of metabolite expression in magnoliid 
taxa, we combined Phylogenetic Eigenvector Maps (PEMs) with metabolite expression 
information for the 69 species in the phylogeny. Ten species (whose actual metabolite 
expression was already known, but here represent ‘unknown’ species) were selected to 
best represent the diversity of genera, different phylogenetic clusters and different 
magnoliid families in the phylogeny and were used as target taxa to validate the 




moschatum Labill. (Atherospermataceae), Beilschmiedia tawa (A.Cunn.) Benth. & 
Hook.f. ex Kirk (Lauraceae), Cryptocarya brassii C.K.Allen (Lauraceae), Doryphora 
sassafras Endl. (Atherospermataceae), Endiandra bessaphila B.Hyland (Lauraceae), 
Hedycarya angustifolia A.Cunn (Monimiaceae), Litsea australis B.Hyland 
(Lauraceae), Piper auritum Kunth (Piperaceae), Tasmannia lanceolata (Poir.) A.C.Sm. 
(Winteraceae) and Wilkiea macrophylla (A.Cunn.) A.DC (Monimiaceae). In selecting 
the metabolites for prediction purposes, the metabolites were chosen that had 
previously been recorded through literature survey in the target taxa (based on Chapter 
two). Phylogenetic Eigenvector Maps were produced for ten metabolites (see Table 5.1) 
which were scored as either absent/present across the species in our phylogeny.  
 
 
Figure 5.2: Phylogenetic hypothesis for super order Magnolianae with target taxa 
highlighted in red boxes (Colour coding according to taxonomic family- black = 
Atherospermataceae, green = Piperaceae, turquoise = Eupomataceae, pink = 




Table 5.1: Bioactive metabolites previously characterised from magnoliid families that 
were also putatively identified in this study 
 
PEMs uses a matrix containing the graphic structure of a phylogeny to calculate 
eigenvectors. The eigenvector is subsequently used in predictive modelling to obtain 
the trait values for missing species. These statistical tests were performed using the 
MPSEM R3.5.1. Package (Guénard et al., 2013). For the PEM, the steepness parameter 
(a) was set to 0 to indicate gradual divergent evolution across branches (as predicted by 
Brownian motion). The rate of evolution was considered to be constant and set to 1 
across the phylogeny.  
The ten bioactive metabolites above were used as target traits to obtain the predictions 
for the presence of the metabolites in these ‘unknown’ species. The predictions take the 
form of a number between 0 and 1, equivalent to the probability that metabolite is 
present. In addition to a quantitative estimate of this probability, we produced a 
categorical prediction of presence/absence of the metabolite in a target taxon. The 
metabolite was predicted to be present if the PEM-predicted value was >0.5. Similarly 
Bioactive metabolite Reference 
camphor (Liu et al., 2016, Zhou and Yan, 2016) 
chlorogenic acid (Fang et al., 2010, Lu et al., 2011) 
cinnamomumolide (Yu et al., 2012) 
cryptocaryolone (Smith and O Doherty, 2003) 
daphnoline (Bick et al., 1960) 
kaempferol (De Almeida et al., 1998) 
myristicin (Charlwood, 1993) 
piperine (Sunila and Kuttan, 2004, Scott et al., 2007, Gorgani et 
al., 2017, Shang et al., 2017) 
polygodial (Loder, 1962, Charlwood, 1993) 




the metabolite was rated as absent if the predicted value was <0.5 (here all values below 
zero were restricted as 0 and all values above 1 were restricted as 1). The predicted 
values were then compared with the observed presence of the metabolites, to assess the 
accuracy of the prediction.  
 
5.4 Results 
The strength of the phylogenetic signal differed between metabolites (Table 5.2). For 
example chlorogenic acid had a strong, significant phylogenetic signal; polygodial had 
a weak, but significant phylogenetic signal, and myristicin had no phylogenetic signal 
and was statistically indistinguishable from a random distribution across the phylogeny.  
Table 5.2: Phylogenetic signal in bioactive specialised metabolites identified as 
magnoliids specifics in the UPLC-MS/MS metabolomic analysis 
P >0.05 indicates that the observed value is not significantly different from the given D 




D value P (D=1) P (D=0)  
metabolites with significant phylogenetic signal  
camphor -6.205* 0 0.904  
chlorogenic acid 0.251* 0.012 0.299 
kaempferol 0.531* 0 0.002  
piperine 0.457* 0 0.014  
polygodial 0.774* 0.043 0  
rutin 0.453* 0.003 0.094 
metabolites with no significant phylogenetic signal 
cinnamomumolide 0.953 0.35 0 
cryptocaryolone 0.200 0.056 0.503 
daphnoline 0.677 0.074 0.067 




The presence of the above metabolites was calculated using Phylogenetic Eigenvector 
Mapping for the ten selected species. Table 5.3 shows a comparison of the actual 
metabolite content, observed presence/absence of metabolite, predicted presence/ 
absence of metabolite and the actual predicted output from PEM. In a total of ten 
instances the predictions were contradictory to the observed metabolite 




Table 5.3: The metabolomic data predictions using PEM compared against the observed metabolite contents, observed absence/presence of the 










































Atherosperma moschatum 640329 1 1 1.00 0 0 0 0.00 6073711 1 0 0.17
Beilschmiedia tawa 327567 1 1 1.00 0 0 0 -0.01 0 0 0 0.05
Cryptocarya brassii 3465490 1 1 1.00 0 0 0 0.00 0 0 0 0.06
Doryphora sassafras 399305 1 1 1.00 0 0 0 0.00 0 0 0 -0.04
Endiandra bessaphila  408029 1 1 1.00 0 0 0 0.00 0 0 0 0.01
Hedycarya angustifolia 1839928 1 1 1.00 0 0 0 0.45 0 0 0 0.38
Litsea australis 328068 1 1 1.00 0 0 0 -0.01 0 0 0 0.00
Piper auritum 562202 1 1 1.00 0 0 0 0.00 0 0 1 2.27
Tasmannia lanceolata 692116 1 1 1.00 0 0 0 0.41 0 0 0 0.04









































Atherosperma moschatum 0 0 0 -0.06 0 0 1 0.83 0 0 1 0.75
Beilschmiedia tawa 0 0 0 0.01 10288755 1 1 1.10 27022 1 1 1.11
Cryptocarya brassii 0 0 0 -0.12 0 0 0 0.01 0 0 0 0.20
Doryphora sassafras 0 0 0 -0.18 1006996 1 1 0.68 113261 1 1 1.03
Endiandra bessaphila  131112 1 1 1.00 76550 1 0 0.01 326179 1 0 0.24
Hedycarya angustifolia 105978 1 1 0.67 4152180 1 1 0.60 273812 1 1 0.54
Litsea australis 371120 1 1 0.99 53404 1 1 1.00 85470 1 1 1.13
Piper auritum 0 0 1 0.94 15048 1 0 0.05 0 0 0 0.23
Tasmannia lanceolata 0 0 0 0.05 0 0 1 0.70 0 0 0 0.44
Wilkiea macrophylla 0 0 0 0.43 0 0 0 0.14 0 0 0 0.01
Polygodial


















































Atherosperma moschatum 0 0 0.34 0 5248141 1 0.87 1 0 0 0.09 0
Beilschmiedia tawa 0 0 -0.11 0 0 0 0.28 0 0 0 -0.06 0
Cryptocarya brassii 0 0 -0.06 0 705460 1 1.10 1 0 0 -0.03 0
Doryphora sassafras 230842 1 0.87 1 1117931 1 0.83 1 0 0 -0.02 0
Endiandra bessaphila  0 0 -0.29 0 0 0 0.20 0 0 0 0.03 0
Hedycarya angustifolia 0 0 0.22 0 50171 1 1.07 1 0 0 0.05 0
Litsea australis 0 0 0.90 1 99818 1 1.01 1 0 0 0.00 0
Piper auritum 0 0 -0.06 0 43635 1 1.10 1 0 0 0.11 0
Tasmannia lanceolata 0 0 0.38 0 317458 1 0.88 1 0 0 0.35 0















Atherosperma moschatum 9248835 1 1.00 1
Beilschmiedia tawa 44014 1 1.00 1
Cryptocarya brassii 434961 1 1.00 1
Doryphora sassafras 21200000 1 1.00 1
Endiandra bessaphila 1917890 1 0.08 0
Hedycarya angustifolia 1453355 1 1.00 1
Litsea australis 343199 1 1.00 1
Piper auritum 21600000 1 1.00 1
Tasmannia lanceolata 203586 1 1.00 1







The above results are summarised as percentage of correct predictions in respect to each 
metabolite. Overall the predictions were > 60% accurate for absence/presence. 
Surprisingly, though, the accuracy of the predictions was not necessarily higher when 
the phylogenetic signal was stronger (Table 5.4; Spearman’s rank correlation of 
relationship of D metric to accuracy of prediction: rs = -0.316, df = 8, P = 0.4374-Figure 
5.2), although the degree of accuracy of prediction is also related to the proportion of 
species showing presence (or absence) of the trait, with presence of ubiquitous 
(proportion close to 100%- camphor, cryptocaryolone and cinnamomumolide) or 
absence of rare compounds (proportion close to 0%- chlorogenic acid and daphnoline)  
having higher predictive capacity (Table 5.4). Intriguingly, for metabolites where no 
phylogenetic signal was observed the predictions were still accurate in over 90% of the 









































Table 5.4: Percentage of accurate predictions in respect to ten metabolites for ten taxa 
compared with the phylogenetic signal strength and proportion of the total species that 
express that metabolite. 




We successfully used Phylogenetic Eigenvector Mapping to predict the 
presence/absence of known bioactive metabolites in Australasian magnoliids. Such an 
approach could potentially be informative in identifying medicinal properties in plants, 
when metabolomic profile data are unavailable for all the taxa in a given phylogeny. In 
our analysis of ten metabolites for ten selected target species, the PEM predicted values 
for the presence/absence of metabolites with >60% accuracy. Six of these metabolites 
were compounds with significant phylogenetic signal (i.e. their distribution across the 
phylogeny is non-random), as indicated by the D metric. Intriguingly, the accuracy of 
the predictions were generally as good with traits with poor phylogenetic signal as with 
those with strong phylogenetic signal. However, this pattern may be confounded by the 





the metabolite (%) 
Strength of 
phylogenetic 
signal (D value)  
camphor 100 99 -6.205* 
chlorogenic acid 100 6 0.251* 
rutin 80 13 0.453* 
piperine 90 35 0.457* 
kaempferol 60 49 0.531* 
polygodial 80 50 0.770* 
myristicin 90 34 1.018 
cinnamomumolide 100 82 0.953 
daphnoline 100 7 0.677 




relative proportions of presence or absence of the compounds among the test species 
generally, with the presence of ubiquitous compounds (or absence of rare compounds) 
being easy to predict simply because of their ubiquity (or rarity). Most applications of 
PEM have been on continuous traits (as morphological or physiological traits) (Guénard 
et al., 2013, Diniz-Filho et al., 2014, Diniz-Filho et al., 2015). The predictive accuracy 
of PEM being used on discrete traits remains to be formally tested. However, our results 
indicate that the approach is useful. 
Overall accuracy of the predictions for metabolomic profiles may also depend upon 
how the trait is expressed by model species in the phylogeny. Not all species within a 
given clade express the same specialised metabolite, and this may lead to wrong 
predictions. For example, our analysis wrongly predicted the presence of piperine in 
Piper auritum, and indeed not all the Piper species in our sample produce piperine. 
Piperine is a characteristic metabolic for the family Piperales which accounts for much 
of the spice and medicinal properties of the clade (Gorgani et al., 2017). Such variation 
in expression of metabolites across species of the same genus could be due to 
differences in gene expression or eco-physiological factors (Figueiredo et al., 2008). 
As an example, it has been found that depending on the rhizosphere (root microbial 
flora) the synthesis of piperine varies among individuals (Paul and Sarma, 2006). Many 
Piper species produce piper amides (including piperine) which provide similar defence 
functions to plants. Yet the factors effecting this divergence have not been elucidated 
(Kato and Furlan, 2007). Therefore in instances where the randomly chosen model 
species in a given phylogeny does not express the metabolite, but the majority of the 
related species do, phylogenetic eigenvector mapping is likely to yield inaccurate 
results. Further, when relying on experimental data, the observed absence of a 
metabolite could also be due to limitations of detection of the metabolite (due to 
intensity thresholds). In such instances increasing the replicates of species could 
provide more accurate information for the presence/absence of a metabolite.  
The rate of evolution is typically kept constant across the phylogeny in previous uses 
of PEM in assessing the among-lineage variability of a trait (Molina-Venegas et al., 
2018). However, this may not be a realistic evolutionary model. As stated above 
metabolomic traits are not always expressed comparatively across related species. For 




synthesis enzymes has caused spearmint plants to lose the production of certain terpenes 
(C6-oxygenated monoterpene) and produce a group of new terpenes (C3-oxygenated 
p-menthane monoterpenes) (Croteau et al., 1991, Firn and Jones, 2000). These 
mutations in genes could occur randomly across species and be passed on across 
lineages through genetic drift, or as a result of selection in particular environments. 
Additionally, these metabolomic traits have been found to show only intermediate 
heritability (Soltis and Kliebenstein, 2015). Further, previous studies on phylogenetic 
signal of medicinal metabolites in plants have shown a phylogenetic signal that is 
significant but not strong (Rønsted et al., 2012, Ernst et al., 2016). Hence, one 
alternative approach to improve predictive potential is to specify different models of 
evolution for a single phylogeny for metabolomic traits (as different rates of evolution 
and steepness parameters in different lineages). Simply, the rate of evolution of a trait 
could then be calculated as the amount of trait change between ancestor and descendant 
lineages, then standardized by the time of divergence (Adams, 2012). Although it is 
hard to specify evolutionary rates without studying the evolutionary model of the trait, 
this could be done using existing methods such as metrics of rate evolution as Darwins, 
Haldanes and Mahalanobis distances as well as more recently introduced likelihood 
based approaches on a phylogeny, based on a Brownian motion model of evolution 
(Adams, 2012).  
Environmental interactions also play a major role in specialised metabolite expression 
across plant lineages. Specialised metabolites are defensive compounds produced by 
plants in response to herbivory (Ehrlich and Raven, 1964). The influence of specific 
herbivores can give rise to co-evolution between the two taxa, hence making the related 
plant groups produce the same specialised metabolite with increased toxicity (Zangerl 
et al., 2003, Toju and Sota, 2006, Edger et al., 2015). Therefore, depending on the 
extent of herbivory, metabolite content across species can vary. Recent research 
indicate that chemical evolution may also drive plant lineage diversification, according 
to coevolutionary theory (Sedio, 2017). Hence, the association between the phylogeny 
and the evolutionary rate of chemical characters could also be stronger than what is 
expected. In such instances, phylogenetic predictions (based on PEM) will not be 




Ecological traits also impact the expression of certain secondary metabolites. Abiotic 
stressors such as altitude, salinity, temperature and water may also act in regulating the 
expression of these metabolites (Spitaler et al., 2006, Sampaio et al., 2016). Recent 
research showed, that the metabolite differences across populations of a model species 
Plantago major L. (broadleaf plantain) were mostly determined by geographic region, 
followed by soil pH (Iwanycki Ahlstrand et al., 2018). In such instances, the abiotic 
factors could also be used as predictors of the expression of certain metabolites.  
Out of the target taxa Atherosperma moschatum, Doryphora sassafras, Hedycarya 
angustifolia, Piper auritum and Tasmannia lanceolata has previously documented 
medicinal uses (Martínez et al., 1996, Setzer et al., 2001, Buchanan et al., 2009, Lassak 
and Mccarthy, 2011, Winnett et al., 2014). The rest of the target taxa have no 
documented medicinal uses (Beilschmiedia tawa, Cryptocarya brassii, Endiandra 
bessaphila, Litsea australis and Wilkiea macrophylla). The overall objective of 
applying PEM to metabolomic traits of magnoliids was to predict the medicinal 
potential of the latter (Table 5.5). This information could therefore be mined from the 
results (Table 5.3), by comparing the observed presence to the PEM-based predicted 
presence of the bioactive metabolites for the latter taxa.  
 
Table 5.5: Potential medicinal taxa for further investigation: Based on observed 
presence and accurate PEM predicted presence  
Bioactive metabolite Potential medicinal taxa expressing the metabolite  
camphor Beilschmiedia tawa 
Cryptocarya brassii 
Endiandra bessaphila 
Litsea australis  
Wilkiea macrophylla  
chlorogenic acid Wilkiea macrophylla 
cinnamomumolide Cryptocarya brassii  




Bioactive metabolite Potential medicinal taxa expressing the metabolite  
Wilkiea macrophylla 
cryptocaryolone  Beilschmiedia tawa  
Cryptocarya brassii  
Endiandra bessaphila   
Litsea australis  
Wilkiea macrophylla 
kaempferol Beilschmiedia tawa 
Endiandra bessaphila 
Litsea australis  
piperine  Endiandra bessaphila 
Litsea australis 
polygodial Beilschmiedia tawa 
Litsea australis  
rutin Wilkiea macrophylla 
PEM offers the capacity to predict metabolite expression (and hence medicinal 
potential) with good to very good accuracy. Our assessment is based on predicting the 
presence/absence of a metabolite of known medicinal importance for the magnoliid 
clade. In case where the predictive capacity is lower, it may be important to consider 
the evolutionary rate of the metabolomic trait across the phylogeny, and other 
ecological covariates to derive more accurate prediction of the medicinal potential of 
the target taxa using known taxa. Further in order to have better predictions a small sub 
sample of a phylogeny could be analysed, so that target species have close ancestry 
with model species. In this case study, the aim was to test the power of the phylogeny 
to predict target compounds in uninvestigated species. For future drug lead discovery, 
it may be more relevant to investigate species which would likely contain other 
bioactive compounds than already known leads. In this case, the phylogenetic approach 
may be combined with information about traditional use, which could help identify 




6. APPENDICES  














Figure 6.1: Thermo Fisher Scientific Compound Discoverer 2.1 
(www.thermofisher.com) custom library data base development process (which was 
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Table 6.1: Sample collection information 
 
Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Canellales Winteraceae Pseudowintera Pseudowintera_colorata_N
_9 
NZ Auckland Botanic 
Gardens Manurewa 
15/03/2017 NA 
Canellales Winteraceae Pseudowintera Pseudowintera_insperata_N
_10 
NZ Auckland Botanic 
Gardens Manurewa 
15/03/2017 NA 
Canellales Winteraceae Pseudowintera Pseudowintera_axillaris_N_
8 




Canellales Winteraceae Tasmannia Tasmannia_insipida_NSW
MA_21 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 861470 
Canellales Winteraceae Tasmannia Tasmannia_xerophyila_NS
WMA__18 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 881461 
Canellales Winteraceae Tasmannia Tasmannia_lanceolata_NS
WMT_5 
AU Blue Mountain 
Botanic Garden 
12/05/2016 871170 
Canellales Winteraceae Tasmannia Tasmannia_insipida_SAML
_8 
AU Mount Lofty Botanic 
Gardens 
14/11/2016 W923357 
Canellales Winteraceae Tasmannia Tasmannia_stipitata_SAML
_12 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Canellales Winteraceae Tasmannia Tasmannia_purpurascens_S
AML_5 




Canellales Winteraceae Tasmannia Tasmannia_membranea_VI
CB_11 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Canellales Winteraceae Tasmannia Tasmannia_stipitata_VICB_
5 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Apollonias Apollonias_barbujana_NS
WS_12 


















Laurales Lauraceae Beilschmiedia Beilschmiedia_obtusifolia_S
AAB_12 
AU Adelaide Botanic 
Gardens 
16/11/2015 W862332 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Beilschmiedia Beilschmiedia_tawaroa_N_
18 
NZ Auckland University 
city campus 
15/03/2017 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_collina_QLD
BC_14 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_elliptica_QL
DBC_42 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_peninsularis
_QLDBC_1 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_tawa_SAML
_18 
AU Mount Lofty Botanic 
Gardens 
14/11/2016 G932003 
Laurales Lauraceae Beilschmiedia Beilschmiedia_tarairi_VICA
5 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_tooram_NS
WS_14 
AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 
Laurales Lauraceae Beilschmiedia Beilschmiedia_tooram_NS
WS_30 
AU Royal Botanic Garden 
Sydney 
9/05/2016 4149048 




Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Cassytha Cassytha_glabella_VIC_A1
0 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Cassytha Cassytha_melonocarpa_VI
C_A7 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Cinnamomum Cinnamomum_oliveri_QLD
BC_41 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cinnamomum Cinnamomum_virens_VICC
_4 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Cinnamomum Cinnamomum_baileyanum_
NSWS_19 
AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 
Laurales Lauraceae Cinnamomum Cinnamomum_burmannii_N
SWS_11 
AU Royal Botanic Garden 
Sydney 
9/05/2016 16819 
Laurales Lauraceae Cinnamomum Cinnamomum_verum_NSW
S_7 
AU Royal Botanic Garden 
Sydney 
9/05/2016 18084 
Laurales Lauraceae Cryptocarya Cryptocarya_mackinnonian
a _SAAB_9 
AU Adelaide Botanic 
Gardens 
16/11/2015 862335 
Laurales Lauraceae Cryptocarya Cryptocarya_microneura_S
AAB_23 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Cryptocarya Cryptocarya_obovata_SAA
B_15 
AU Adelaide Botanic 
Gardens 
16/11/2015 G832357 
Laurales Lauraceae Cryptocarya Cryptocarya_williwilliana_
SAAB_21 
AU Adelaide Botanic 
Gardens 
16/11/2015 W890083 
Laurales Lauraceae Cryptocarya Cryptocarya_bidwillii_NSW
MA_11 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 850808 
Laurales Lauraceae Cryptocarya Cryptocarya_erythroxylon_
NSWMA_16 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 20150261 
Laurales Lauraceae Cryptocarya Cryptocarya_foetida_NSM
MA_1 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 4149934 
Laurales Lauraceae Cryptocarya Cryptocarya_glaucescens_
NSWMA_20 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 20140278 
Laurales Lauraceae Cryptocarya Cryptocarya_laevigata_NS
WMA_6 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 861640 
Laurales Lauraceae Cryptocarya Cryptocarya_microneura_N
SWMA_17 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 20130305 
Laurales Lauraceae Cryptocarya Cryptocarya_alba_NSWMT
_3 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Cryptocarya Cryptocarya_brassii_QLDB
C_12 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_cocosoides_Q
LDBC_8 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_cunninghamii
_QLDBC_4 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_glaucescens_
QLDBC_39 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_meisneriana_
QLDBC_28 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_murrayi_QLD
BC_9 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_oblata_QLDB
C_21 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 952823 
Laurales Lauraceae Cryptocarya Cryptocarya_triplinervis_Q
LDBC_16 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_hypospodia_V
ICA_8 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Cryptocarya Cryptocarya_sclerophylla_
VICB_17 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Cryptocarya Cryptocarya_foetida_NSMS
_1 
AU Royal Botanic Garden 
Sydney 
9/05/2016 893893 
Laurales Lauraceae Cryptocarya Cryptocarya_obovata_NSW
S_17 
AU Royal Botanic Garden 
Sydney 
9/05/2016 13405 
Laurales Lauraceae Cryptocarya  Cryptocarya 
_rigida_SAML_10 




Laurales Lauraceae Cryptocarya  Cryptocarya 
_rigida_QLDBC_31 







AU Australian Botanic 





























































AU Royal Botanic Garden 
Sydney 
9/05/2016 20100222 
Laurales Lauraceae Endiandra Endiandra_compressa_SAA
B_7 
AU Adelaide Botanic 
Gardens 
16/11/2015 901407 
Laurales Lauraceae Endiandra Endiandra_hypotephra_SA
AB_8 
AU Adelaide Botanic 
Gardens 
16/11/2015 960118 
Laurales Lauraceae Endiandra Endiandra_virens_SAAB_3 AU Adelaide Botanic 
Gardens 
16/11/2015 895776 
Laurales Lauraceae Endiandra Endiandra_discolor_NSWM
A_7 
AU Australian Botanic 





Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Endiandra Endiandra_globosa_NSWM
A_3 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 820659 
Laurales Lauraceae Endiandra Endiandra_impressicosta_N
SWMA_4 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 862053 
Laurales Lauraceae Endiandra Endiandra_pubens_NSWM
A_5 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 861611 
Laurales Lauraceae Endiandra Endiandra_bessaphila_QL
DBC_29 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_compressa_QL
DBC_7 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_dielsiana_QLD
BC_18 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_impressicosta_Q
LDBC_17 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_longipedicellata
_QLDBC_15 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_microneura_QL
DBC_10 
AU Brisbane Botanic 





Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Endiandra Endiandra_sankeyana_QLD
BC_11 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_sideroxylon_QL
DBC_22 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 201304801
0 
Laurales Lauraceae Endiandra Endiandra_sieberi 
_QLDBC_35 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Endiandra Endiandra_floydii_VICB_1
8 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Endiandra Endiandra_introrsa_VICB_
19 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Lauraceae Endiandra Endiandra_sieberi 
_VICA_11 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Laurales Monimiaceae Hedycarya Hedycarya_arborea_N_13 NZ Auckland University 
city campus 
15/03/2017 NA 
Laurales Monimiaceae Hedycarya Hedycarya_angustifalia_NS
WMT_10 
AU Blue Mountain 
Botanic Garden 
12/05/2016 NA 
Laurales Monimiaceae Hedycarya Hedycarya_loxocarya_QLD
BC_13 
AU Brisbane Botanic 





Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Monimiaceae Hedycarya Hedycarya_angustifalia_SA
ML_1 
AU Mount Lofty Botanic 
Gardens 
5/12/2016 W834314 
Laurales Hernandiaceae Hernandia Hernandia_albiflora_SAAB
_1 
AU Adelaide Botanic 
Gardens 
16/11/2015 960105 
Laurales Hernandiaceae Hernandia Hernandia 
bivalvis_NSWS_1 
AU Royal Botanic Garden 
Sydney 
9/05/2016 8254 
Laurales Hernandiaceae Hernandia Hernandia_cordigera_NSW
S_10 
AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 
Laurales Myristicaceae Horsfieldia Horsfieldia_australiana_QL
DBC_19 
AU Brisbane Botanic 




















AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Lauraceae Litsea Litsea_reticulata_NSWMA_
10 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 920734 
Laurales Lauraceae Litsea Litsea_australis_QLDBC_3
3 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 951759 
Laurales Lauraceae Litsea Litsea_bindoniana_QLDBC
_20 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Litsea Litsea_leefeana_QLDBC_2
7 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 NA 
Laurales Lauraceae Litsea Litsea_calicaris_N_2 NZ The Elms, 15 Mission 
St, Tauranga 
15/03/2017 NA 
Laurales Lauraceae Neolitsea Neolitsea_australiensis_NS
WMA_8 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 850816 
Laurales Lauraceae Neolitsea Neolitsea_dealbata_NSWM
A_9 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 873162 
Laurales Lauraceae Persea Persea_americana_NSWS_
27 
AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Laurales Monimiaceae  Peumus Peumus_boldus_SAML_22 AU Mount Lofty Botanic 
Gardens 
14/11/2016 NA 
Laurales Lauraceae Phoebe Phoebe_nanmu_NSWS_13 AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 
Laurales Monimiaceae Wilkiea Wilkiea_hugeliana_NSWMA
_15 
AU Australian Botanic 
Garden Mount Annan 
14/05/2016 20140861 
Laurales Monimiaceae Wilkiea Wilkiea_macrophylla_QLD
BC_36 
AU Brisbane Botanic 
Garden Mt Coo-Tha 
5/12/2016 963678 
Laurales Monimiaceae Wilkiea Wilkiea_macrophylla_NSW
S_6 





















AU Brisbane Botanic 












Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Piperales Piperaceae Peperomia Peperomia_blandavarFlori
bunda_N_3 
NZ Auckland Zoo, 
Tuatara house 
15/03/2017 NA 
Piperales Piperaceae Piper Piper_excelsum_N_5 NZ Auckland Botanic 
Gardens Manurewa 
15/03/2017 AK364211 




Piperales Piperaceae Piper Piper_peltatum_N_7 NZ Auckland Botanic 
Gardens Manurewa 
15/03/2017 AK364209 
Piperales Piperaceae Piper Piper_excelsum_VICA_13 AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Piperales Piperaceae Piper Piper_novae-
hollandiae_VICB_14 
AU Royal Botanic Garden 
Melbourne 
1/01/2015 NA 
Piperales Piperaceae Piper Piper_auritum_NSWS_37 AU Royal Botanic Garden 
Sydney 
9/05/2016 20110633 
Piperales Piperaceae Piper Piper_betle_S_26 AU Royal Botanic Garden 
Sydney 
9/05/2016 NA 






Order Family Genus Species Identity  Country Location  Date of 
Collection 
Accession 
Piperales Piperaceae Piper Piper_hederaceum_NSWS_
38 
AU Royal Botanic Garden 
Sydney 
9/05/2016 862958 
Piperales Piperaceae Piper Piper_magnificum_NSWS_1
8 
AU Royal Botanic Garden 
Sydney 
9/05/2016 10516 
Piperales Piperaceae Piper Piper_nigrum_NSWS_36 AU Royal Botanic Garden 
Sydney 
9/05/2016 20120159 
Piperales Piperaceae Piper Piper_umbellatum_NSWS_2
2_2 






Table 6.2: Secondary metabolites from magnoliids already identified in literature 
Secondary Metabolite  Metabolite Class Distribution amongst magnoliids * Reference 
actinodaphnine alkaloid Hernandiaceae, Lauraceae  (Afendi et al., 2012) 
apateline alkaloid Atherospermataceae (Bick and Sotheeswaran, 1978) 
atheroline alkaloid Atherospermataceae  (Bick and Douglas, 1965) 
atherospermidine alkaloid Atherospermataceae (Harborne and Baxter, 1993) 
boldine alkaloid  Annonaceae, Atherospermataceae, Lauraceae, 
Monimiaceae  
(Harborne and Baxter, 1999, Afendi et al., 
2012) 
camphor terpene Lauraceae  (Afendi et al., 2012) 
cassythicine alkaloid  Annonaceae, Hernandiaceae, Lauraceae, (Afendi et al., 2012) 
chlorogenic acid phenolic  Lauraceae, Magnoliaceae, Winteraceae  (Konczak et al., 2010, Lu et al., 2011) 
coclaurine alkaloid  Annonaceae, Lauraceae, Magnoliaceae, 
Monimiaceae  
(Liscombe et al., 2005) 
cryptowoline alkaloid  Lauraceae  (Afendi et al., 2012) 
daphnandrine alkaloid Atherospermataceae (Harborne and Baxter, 1993) 
daphnoline alkaloid Atherospermataceae (Bick and Sotheeswaran, 1978) 




Secondary Metabolite  Metabolite Class Distribution amongst magnoliids * Reference 
eugenol terpene  Lauraceae, Piperaceae  (Afendi et al., 2012) 
germacrene D terpene Lauraceae, Piperaceae  (Mundina et al., 1998) 
hedycaryol terpenoid  Monimiaceae  (Wharton et al., 1972) 
isocorydine alkaloid Lauraceae, Annonaceae  (Liscombe et al., 2005, Pérez and Cassels, 
2010, Mason et al., 2016) 
isoquercetin flavonoid Annonaceae, Lauraceae, Piperaceae, 
Winteraceae,  
(Wang et al., 2012) 
johnsonine alkaloid Atherospermataceae (Bick and Sotheeswaran, 1978) 
kaempferol flavonoid Annonaceae, Lauraceae,  (Wang et al., 2012) 
laurotetanine  alkaloid Annonaceae, Hernandiaceae, Lauraceae, 
Monimiaceae, Piperaceae 
(Afendi et al., 2012) 
limonene terpene Piperaceae (Mundina et al., 1998) 
liriodenine alkaloid  Annonaceae, Hernandiaceae, Lauraceae, 
Magnoliaceae  
(Harborne and Baxter, 1993) 
  
micranthine alkaloid Atherospermataceae (Bick and Sotheeswaran, 1978) 




Secondary Metabolite  Metabolite Class Distribution amongst magnoliids * Reference 
myristicin phenolic Lauraceae, Magnoliaceae, Winteraceae, 
Piperaceae  
(Harborne and Baxter, 1993) 
pilloin flavonoid  Winteraceae  (Harborne and Baxter, 1999, Afendi et al., 
2012) 
piperine alkaloid Piperaceae (Gorgani et al., 2017) 
pipernonaline alkaloid Piperaceae (Mckey, 2005) 
polygodial terpene  Canellaceae Winteraceae  (Harborne and Baxter, 1993) 
pukateine alkaloid  Atherospermataceae (Harborne and Baxter, 1999, Afendi et al., 
2012) 
quercetin alkaloid  Lauraceae (Shen et al., 2014) 
repandine alkaloid Atherospermataceae (Bick and Sotheeswaran, 1978) 
safrole phenolic 
 
Lauraceae, Magnoliaceae, Piperaceae 
Monimiaceae Myristicaceae  
(Harborne and Baxter, 1993) 
  


















Sample Retention time Mass Peak area 
PBQC 0 1.68 195.0876 5326074.95 
PBQC 1 1.69 195.0876 6247584.81 
PBQC 2 1.69 195.0877 5443329.01 
PBQC 3 1.69 195.0877 6489635.65 
BQC 4 1.68 195.0878 5924525.71 
PBQC 5 1.68 195.0878 5771580.16 
PBQC 6 1.70 195.0878 5772770.61 
PBQC 7 1.69 195.0878 6509490.79 
PBQC 8 1.69 195.0878 7006505.02 
PBQC 9 1.70 195.0878 6783577.48 
PBQC 10 1.68 195.0878 7250498.94 
PBQC 11 1.68 195.0877 6995653.51 
PBQC 12 1.70 195.0877 6389751.20 
PBQC 13 1.70 195.0877 6481605.23 








This form must be retained by the executive author, within the school or institute in which they 
are based.If the publication is to be included as part of an HDR thesis, a copy of this form must be 
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